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Abstract 
Background: gabapentin and pregabalin are commonly used for relieving neuropathic 
pain, but also could lead to diversion, dependence and tolerance, with adverse effects 
on the central nervous system, especially when co-prescribed with opioids.  The rates 
of prescribing gabapentinoids have significantly increased over the last decade.  
However, limited research has investigated the impact of excessive prescribing, and 
the factors associated with the co-prescribing of opioids and gabapentinoids are 
unknown. 
Objectives: (1) to review existing evidence of the misuse of gabapentin and pregabalin 
systematically; (2) to examine the association between health outcomes/service use 
and co-prescribed opioids and gabapentinoids, after controlling for the potential 
confounders of socio-demographic factors and cancer. 
Methods: (1) published literature on gabapentinoids misuse was searched 
systematically in key medical and pharmacy databases, and papers were selected 
based on inclusion/exclusion criteria (studies of adolescents and children, case studies 
and animal studies and irrelevant studies were excluded).  After data abstraction and 
quality assessment, included citations were synthesised and summarised.  (2) An 
existing dataset of 65,000 individuals in Tayside and Fife who had received at least one 
prescription of an opioid, with corresponding prescribing, healthcare, clinical and socio-
demographic information, was linked with routine data on healthcare outcomes.  
Factors associated with co-prescribing of opioids and gabapentinoids were examined 
by Chi-square testing and logistic regression, stratified by age, sex and socioeconomic 
class.                
Results: (1) 268 citations were found from the initial search, and 15 studies were 
included after study selection.  These studies showed a growing number of 
prescriptions of gabapentinoids and reports of misuse reports internationally.  From 
the observational studies using large databases, among the patients prescribed the 
medicine, the misuse prevalence of pregabalin ranged from 1.0% to 9.6%, and the 
prevalence of gabapentin misuse was 4.8%.  Patients with substance misuse disorder 
were more likely to experience an overdose and to have non-medical use of 
gabapentin and pregabalin.  Other types of included studies were generally of poor 
quality.  (2) The results from data analysis demonstrated Accident and Emergency 
(A&E) attendance (for any cause) and repeated hospital admission were associated 
with co-prescription of opioids and gabapentinoids, after controlling for the potential 
confounding factors such as cancer and age.   
Conclusions: overall evidence implied rising prevalence of gabapentinoid prescribing, 
and a rising trend of gabapentinoid misuse internationally, especially among patients 
with a history of substance misuse.  The co-prescription of opioids and gabapentinoids 
was found to be associated with important socio-demographic and clinical factors.  
These highlight the need and opportunities for research aimed at preventing 
gabapentinoid misuse. 
Keywords: Opioid; Gabapentin; Pregabalin; Misuse; Co-prescription 
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1   Thesis objectives 
This study aimed to investigate the misuse of gabapentinoids and factors associated 
with co-prescribed opioids and gabapentinoids.  The objectives were based on the 
evidence gap identified in this area, and the availability of the data.  To achieve these 
aims, this study contained two projects that related to each other.  One was to review 
existing the evidence around the misuse of gabapentin and pregabalin in the 
population systematically, and to determine the key needs and directions for further 
studies.  The other was a data-linkage study in Tayside and Fife, to examine the health 
outcomes/service use associated with co-prescribed opioids and gabapentinoids, after 
controlling for potential confounders including socio-demographic factors.   
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2   Systematic review: the misuse of prescribed 
gabapentinoids in population 
2.1 Introduction 
Everyone experiences pain.  As an important role in our lives, the feeling of pain is so 
common.  Pain is defined by The International Association for the Study of Pain (IASP) 
as, “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (1).  Pain is classified 
as acute pain and chronic pain by the duration and pathoanatomic characteristics.  
Acute pain has a short duration, and can be relieved by curing the damaged tissue.  
Acute pain can act as a protection of the body.  By implying the damage or potential 
damage of the tissue, it can influence the behaviour to avoid further injury and 
improve healing.  On the contrary, chronic pain is long-term (over three months) and 
not protective (2).  As well as producing the physical symptoms, chronic pain can lead 
to anxiety and depression (3) and affect the health by causing sleep disturbance and 
substance-related disorder (4).  Chronic pain has become a significant problem in 
developed and developing countries.  Chronic pain affects around 20% of the European 
(EU) (5) and the United States population (2), and the prevalence was reported even 
higher in the United Kingdom (UK),  between one-third and one-half of the population 
of the UK (6).   
Chronic pain is categorised into nociceptive pain and neuropathic pain by different 
mechanisms.  Nociceptive pain is caused by actual or threatened damage to non-neural 
tissue and the activation of nociceptors (7), while the definition of neuropathic pain 
given by IASP is “pain arising as a direct consequence of a lesion or disease affecting 
the somatosensory system” (8).  Neuropathic pain results from the damage or 
dysfunction of neural tissue (9), and it is characterised by burning pain, hyperalgesia 
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and allodynia (10).  Diabetes, excessive alcohol intake, HIV infection, spinal cord injury, 
and some complex causes could lead to the damage of the nervous system.  With both 
physical and mental symptoms, pain with neuropathic features is often more severe 
and complex to manage and decreases the quality of life.  The clear mechanisms of 
neuropathic pain are unknown and there could be multiple mechanisms (11).  It is 
recommended to treat neuropathic pain with multiple medications if required, 
combined with patient education (12).  Seven percent of UK and EU populations suffer 
from neuropathic pain (13). 
Gabapentin and pregabalin are indicated as first-line prescribed drugs in national and 
international clinical guidelines and recommended for the treatment of neuropathic 
pain (14).  These two medications, grouped together as gabapentinoids, act by α-2 
delta subunit of presynaptic voltage-dependent calcium channels.  They affect 
chemicals and nerves in the body that are involved in the cause of seizures and some 
types of pain (15).  The Food and Drug Administration (FDA) in the US approved 
gabapentin and pregabalin in 1993 and 2004 under the brand name Neurontin and 
Lyrica for the drug manufacturer Pfizer, respectively (16, 17).  Initially developed to 
treat epilepsy, gabapentinoids are now widely used in neurology, psychiatry and 
primary healthcare (18).  Generally, a typical adult dose of gabapentin for neuropathic 
pain usually starts at 300 mg, and may be increased to up to 3,600 mg a day (19).  The 
maximum dose of pregabalin is 600 mg daily in two divided doses (16).   
However, there are some problems with the use of gabapentin and pregabalin.  The 
treatment with gabapentinoids may involve side effects, like ataxia, dizziness, 
drowsiness, fatigue, fever, nystagmus, sedation, and viral infection (20).  Beside these 
side effects, gabapentin can interact with other medications.  Opioids like hydrocodone 
and morphine can change the amount of gabapentin in the body and oxycodone can 
interact with pregabalin (18).  Moreover, gabapentinoid prescriptions have increased 
significantly in the past decade in Scotland, which cannot simply be explained by the 
growing number of neuropathic pain diagnoses.  A rising trend of gabapentinoid use is 
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related to drug-related death records from prison and substance misuse services.  Also, 
the use of gabapentin and pregabalin has expanded from chronic neuropathic pain to 
other chronic and later acute pain conditions (21), despite a lack of effectiveness in 
these conditions. 
There is an ongoing debate on whether there is an abuse tendency of gabapentinoid 
prescription and an association with drug addiction, dependence and diversion 
internationally.  Though increasing prescriptions were reported in Scotland, data from 
The Health Improvement Network (THIN) database indicate that an overwhelming 
majority of pregabalin prescribing in the UK is consistent with product licensing (22).  In 
other countries the prescriptions for gabapentinoids do not necessarily have the same 
trend.  However, the published evidence is quite limited, the prevalence and patterns 
of prescribing gabapentinoids, and magnitude of the misuse remains unknown.  The 
controversial conclusions on drug safety issues with gabapentinoids need to be 
compared and the abuse patterns need to be summarised worldwide. 
Gabapentinoids prescribed excessively can affect patient safety, and local and national 
prescribing costs (2).  This systematic review aims to describe and summarise current 
published literature on the prevalence of the misuse of prescribed gabapentinoids in 
the population, and the potential factors associated with the misuse.  The results will 
inform local and national strategies to rationalise the prescribing and safety of 
gabapentin and pregabalin, and will give us an idea of evidence gaps on the misuse of 
medicine in treating neuropathic pain and limitations of relevant studies. 
  
13 
 
2.2 Methods 
2.2.1 Search strategy 
Pre-search 
Before the structured systematic search, a rough search of existing and ongoing 
reviews was conducted by searching the key words of free texts in the database of 
Cochrane Database of Systematic Reviews (CDSR).  CDSR contains systematic reviews 
conducted by the Cochrane Collaboration.  The search would give an indication of the 
previous and current studies of systematic review of the misuse of gabapentin and 
pregabalin.       
After pre-search, literature searching with a compliment of internet search and 
reference checking were used to identify the published studies of the misuse of 
prescribed gabapentin and pregabalin.   
Literature search  
To select the key electronic database, I checked previous systematic review studies in 
Medicine (23-25) and found some commonly used biomedical and pharmacological 
databases: MEDLINE, Ovid Embase and Cumulative Index to Nursing and Allied Health 
Literature (CINAHL).  Additionally, the database in the Centre for Reviews and 
Dissemination (CDR) was searched for meta-analyses and systematic reviews, using the 
search strategy and terms.  The CDR database is a resource of meta-analyses and 
systematic reviews in medicine, including Database of Abstracts of Reviews of Effects 
(DARE), Health Technology Assessment (HTA) and National Health Service Economic 
Evaluation Database (NHS EED).  In addition, The Knowledge Network, the national 
knowledge management platform for health and social care in Scotland, was searched, 
finding many results coming from PsycINFO, a database in psychology.  So considering 
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the characteristics of each database and the accessibility of the resources, MEDLINE, 
Ovid Embase, CINAHL, CDR and PsycINFO were chosen as the searching databases. 
The search was conducted in November 2016.  As gabapentin and pregabalin have only 
recently been introduced, a check of the published years would be applied after getting 
the search results and the filter would be set when needed, but there was no 
restriction of published year during the search.  Alerts of my search were set in 
MEDLINE, Ovid Embase and CINAHL (the other two are much smaller databases and 
not available for setting alerts) and I checked the new publishing results until March 
2017.  The information on new published papers would be added only if it was included 
in the study.   
The team for the review (SW, NT and JW) agreed that the keywords should include the 
drug names, the disease neuropathic pain (neuralgia) and “misuse”.  The search was 
the “misuse” and gabapentin/pregabalin/neuropathic pain.  It is clear for the drug 
names: the two drugs (gabapentin, pregabalin), their trade names (Neurontin, Lyrica) 
and the classification (gabapentinoids).  To better summarise “misuse”, I first discussed 
with the review team and listed some keywords: misuse, abuse, overdose, addiction, 
diversion, dependence.  Then I searched Medical Subject Headings (MeSH) terms in 
MEDLINE, and used the phrases of “prescription drug misuse”, “substance-related 
disorders”, “prescription drug overuse”, and “prescription drug diversion”.  Other 
descriptions of “misuse” related to these meanings would be automatically searched as 
well when I used MeSH terms.  The search was a combination of free texts and MeSH 
terms.  The search strategy for each database was almost the same with tiny 
adjustments to fit the different databases.  The inclusion/exclusion Criteria were 
generated based on Population, Intervention, Comparators, Outcomes and Study 
Designs (PICOS) to express the research question more detailed and specifically. 
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All kinds of study types were included except for case studies, as single cases could not 
reflect the pattern of the whole population.  There was a specific focus on human 
population data, so animal studies were excluded.  Studies on special groups (e.g. 
prisoner studies, post-mortem studies) were excluded since this study was describing 
the prevalence in the general population.  Due to the limited resources to conduct the 
study and being unable to employ a translator, the search was restricted to English 
language documents only, and non-English language papers were excluded.  As 
gabapentinoids can also be used for treating substance disorders caused by other 
Research question How much misuse of prescribed gabapentin and pregabalin is 
there in the population? 
  
Inclusion criteria 
Population: Adults in the general population 
Interventions: prescribed gabapentin or pregabalin 
Outcomes: Misuse, addiction, abuse, drug diversion, dependence 
Study designs: Observational studies of a large dataset, survey, cohort studies 
  
Exclusion criteria 
Population: Studies of children, adolescents, prisoners and post-mortem 
studies  
Outcomes: Using gabapentinoids as a medication to treat dependence on 
other drugs 
Study designs: Case studies, animal studies 
Language: Non-English studies 
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drugs (e.g. Opioids) in some countries, some studies with the keywords of substance 
disorders were actually focused on the treatment rather than misuse, and these 
citations were excluded.   
Internet resources and reference scanning 
As there are limited research groups and institutes conducting study of this topic and 
some reports by the government or institute may not get published in peer-reviewed 
journals, I manually searched for publications from these research teams and checked 
their websites on the Internet.  After the search and selection of the citations from key 
electronic medical databases, I scanned the reference lists of included papers to see if 
there were any additional citations that were missed in the search, to add 
complementary citations.  This system could also check if the literature search was 
good quality capturing most studies.    
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2.2.2 Paper selection  
Each database was searched separately and all the results were combined and 
imported to Endnote, a software package to manage references.  Endnote can exclude 
duplications automatically, and a manual check for duplicates was also applied.  The 
review team (SW, NT and JW) had a pre-selection of a few citations and discussed how 
to apply the inclusion/exclusion criteria in practice.  The titles of remaining citations 
were screened by two reviewers (SW and NT) independently.  The reviewers scanned 
the titles and chose to either exclude the paper (exclude) or have a look at the abstract 
of this paper (pass).  Only if the paper was not selected by either reviewer, this citation 
would be excluded.  Following the title review, the remaining papers were screened by 
reviewing the abstracts.  Editorials without new data only commenting on other 
studies were excluded.  Then the full text screening was identified by two reviewers 
(SW and NT).  If they could not reach an agreement after discussion, a third reviewer 
(JW) would make the decision whether to include this citation or not.  Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart would 
be made to show the process of the selection.   
2.2.3 Data abstraction 
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
checklist (Appendix 1) (26) is widely used for checking items that should be included in 
observational studies.  In this study the STROBE checklist was used as the data 
abstraction form, since most included studies were observational studies and the 
STROBE checklist is suitable for collecting the relevant information.  STROBE was 
chosen rather than using other abstraction forms because it is connected to the quality 
assessment, and can make it easier to assess in the next step.  According to the 
checklist, the title, abstract, introduction, methods (including the study design, setting, 
bias, study size etc.), results, discussions and other information would be summarised 
in the form.   
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2.2.4 Quality assessment 
Quality assessment tools were used to ensure the results were more rigorous with 
critical evaluation.  According to the characteristics of study types of included citations, 
the assessment tools were modified based on several widely used tools.   
The form of Quality Assessment Tool for Observational Cohort and Cross-sectional 
Studies by National Heart, Lung and Blood Institute (NHLBI) (Appendix 2) was used as 
the basis for the modified checklists.  The review studies would be assessed by CASP 
tool (Appendix 3).  NHLBI checklist combined with checklist from Critical Appraisal Skills 
Programme (CASP) (Appendix 4) and Joanna Briggs Institute (JBI) (Appendix 5) was 
used for assessing the quality of cohort studies and analytical cross sectional studies.  
The assessment of the surveys was based on the Survey Assessment Framework from 
Circum Network (Appendix 6). 
2.2.5 Data summary 
The included papers were summarised in tables by different study types.  The summary 
tables were designed based on the characteristics of the study type.  The tables mainly 
described the information of the study (author, publishes year and study region), study 
population/sample/cohort and their characteristics/recruitment, study period, 
prevalence/rate of misuse and main findings (trend of the misuse and potential 
factors). 
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2.3 Results 
2.3.1 Study characteristics 
From the pre-search, there were no existing or ongoing reviews for the same research 
question with the same search strategy as this systematic review in CDSR.  The 
literature search included 468 citations from the key medical databases.  After the 
selection of titles, 115 citations remained for abstract screening.  The published years 
of these 115 citations ranged from 2001 to 2016, so no filters were required to restrict 
the publication year in the selection.   
The reference checking found four new studies, including one case study, one prisoner 
study, and one post-mortem study, which were against the inclusion criteria.  The 
remaining one of the four studies was included.  The very small number of newly 
identified studies also implied the search had a good quality.  The internet search 
found one relevant study of systematic review by Canadian Agency for Drugs and 
Technologies in Health (CADTH) that were not published in a journal.   
So overall two extra citations (one from the reference lists and one from the internet 
search) were added to full text scanning.  The flow chart (Figure 1) shows the process 
of study selection and exclusion.  And finally 15 citations (12 journal articles and 3 
editorials) were identified.  Among these, there were six observational studies of a 
large database analysis, four questionnaire-based surveys, two cohort studies and 
three related systematic reviews.  There were three new studies published after the 
initial search but they are not relevant, so they were not shown in the overall search 
flow chart.  The majority of the included studies were published after 2015 and the 
earliest study was published in 2012.   
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15 articles 
included 
Medline 
268 Citations 
Ovid Embase 
295 Citations 
CINAHL 
89 Citations 
PsycINFO 
68 Citations 
CRD 
6 Citations 
 468 Non-duplicate   
citations 
Exclusion 
criteria: 
Animal study 
Case report 
Treatment  
355 
Articles 
excluded 
after title 
screening 
96 Articles 
excluded 
after 
abstract 
screening 
 19 articles retrieved 
Full text 
scanning 
 2 article from 
reference lists 
and internet 
Figure 1.  Flow chart of study selection 
21 
 
2.3.2 Main findings  
The epidemiological studies of observational analysis of large databases were all from 
EU, and other studies were from the US, EU and UK.  From the search, there were 
twenty-nine, nine and three studies of non-English languages from MEDLINE, Ovid 
Embase and CINAHL, respectively.  But they were all excluded because of language 
limitation.  This restriction might cause the bias on examining the pattern of global 
distribution of the epidemic.  However, these non-English studies are mostly from the 
EU, so this would not influence the conclusion of that the misuse was reported mainly 
in the US, EU and UK. 
Large database analysis 
Five out of six observational studies with large databases investigated the misuse and 
abuse of pregabalin, the remaining one study described both gabapentin and 
pregabalin misuse.  These studies regarded the study population as patients who were 
prescribed gabapentin or pregabalin, and calculated prevalence by identifying the 
cases and reports of misuse among those medicine users.  The prevalence of misuse 
cases among prescribed pregabalin patients ranged from 1.0% to 9.6%, and the 
prevalence for gabapentin misuse cases was reported as 4.8% (Table 1).   
Two studies found little association between the exposure to pregabalin and drug 
misuse, with a small misuse prevalence of 1.0% and 1.5% among pregabalin users.  
Asomaning et al (22) found there was not misuse of pregabalin and a history of 
substance abuse was not a risk factor for the overdose.  The authors of this study were 
employees of Pfizer, the commercial company producing gabapentin and pregabalin.  
They tried to find out the reason why their findings were not consistent with other 
studies, and compared their study population with the study population in a Swedish 
study (30).  The demographic characteristics of the two studies were similar, but the 
prescription and diagnosis patterns were quite different.  They discussed that this 
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might be due to the data used in the study.  With the limited information of indication 
and doses of the prescriptions, the data was actually not suitable for analysing the 
prevalence of pregabalin misuse.  Bossard et al (28) searched for the misuse reports of 
pregabalin in French Pharmacovigilance Database (FPVD).  Though the database was 
large with 184,310 reports, only eight of them reported misuse of pregabalin, and the 
first case was reported quite late, 2010.  This implied the potential pitfalls of 
spontaneous reporting systems.   
Another four studies found the misuse trend in the population and identified the 
factors related to the drug misuse among the users.  In summary, male gender, 
younger age, lower income and substance abuse history could be potentially 
associated with drug abuse.  Chiappini et al (27) examined both gabapentin and 
pregabalin, which was the only observational study to examine both drugs.  In 
comparison, they found a higher reporting ratio of misuse coming from pregabalin 
users.  Most misuse reports from both gabapentin and pregabalin involved opioid 
prescribing and female patients.  However, Schjerning et al (31) found male gender was 
a risk factor for the misuse of pregabalin, as well as prescription of anti-psychotics.  The 
Swedish study also found males had a higher risk of misuse of pregabalin, and also low 
income groups and people with a history of substance abuse disorders (30).  Gahr et al 
(29) analysed the dataset of BfArM and found male sex and a history of polydrug use 
were risk factors for pregabalin misuse.
 Table 1.  Summary of gabapentinoid misuse in observational studies analysing large databases 
  
Study Study population Data source Definition Prevalence Main findings 
Chiappini           
2016                       
EU (27) 
n=115,616 for 
pregabalin                     
n=90,166 for 
gabapentin 
EudraVigilance 
(EV) database 
from European 
Medicines Agency 
(EMA) 
Intentional 
product misuse, 
drug dependence 
and drug abuse 
etc. in Medical 
Dictionary for 
Adverse Drug 
Reactions (ADR) 
6.6% for 
pregabalin           
(7,639/115,616)                 
4.8% for 
gabapentin                  
(4,301/90,166) 
Rising trend;                 
Female more;               
More reports of 
pregabalin  
Adverse drug reaction 
reports relating to 
pregabalin/gabapentin 
03/2006-15/07/2015 
for pregabalin                       
03/2004-15/07/2015 
for gabapentin 
 
Asomaning         
2016                                
UK (22) 
n=18,951 The Health 
Improvement 
Network (THIN) 
primary care 
database in UK 
READ codes 
(diagnosis 
codes) as proxy;                                
Overdose of 600 
mg/day 
1.0% 
(136/13,480) 
The proportion of 
overdose was small;                                  
History of substance 
abuse had no effect 
Prescribed pregabalin, 
first prescribed over 
12 years old 
09/2004-07/2009 
 
Schjerning                                              
2016                                                   
Denmark 
(31) 
n=80,868 Danish 
Nationwide 
Prescription 
Registry 
Anatomical 
Therapeutic 
Chemical (ATC) 
Codes and 
Defined Daily 
Dose (DDD); ICD-
10;                                                 
Overdose of 600 
mg/day 
9.6% for 6 
months                                   
(4,090/42,520)              
6.5% for 12 
months                                                     
(2,765/42,520) 
Male gender, 
prescription of 
antipsychotics and 
benzodiazepines 
were risk factors
Exposed to at least 
one prescription of 
pregabalin  
2004-2013 
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 Table 1.  (Continued) 
  
Study 
population 
Data source Define Prevalence Main findings 
Bossard                                           
2016                                                     
France (28) 
n=521 French 
Pharmacovigilance 
Database (FPVD) 
Medical Dictionary 
for Adverse Drug 
Reactions (ADR) 
1.5%                                                             
(8/521) 
No significant
association between 
exposure to 
pregabalin and drug 
abuse or dependence 
Exposure to
pregabalin 
01/01/2010-
31/12/2015 
Boden                                                                  
2014                                                                           
Sweden (30) 
n=48,550 Swedish National 
Health and 
Population Registry 
Overdose of 600 
mg/day 
8.5%                                                       
(4,130/48,550) 
Male gender, 18-29 
years age, low 
income, diagnosed 
with epilepsy, 
substance use 
disorder and abuse 
history were risk 
factors 
 
Dispensed ≥3
prescriptions of 
pregabalin 
06/2006-
12/2009 
Gahr                                                           
2013                                                
Germany 
(29) 
n=1,552 German Federal 
Institute for Drugs 
and Medical 
Devices (BfArM) 
standardised 
Medical Dictionary 
for Regulartory 
Activities (MeDRA) 
query (SMQ) 
3.5%                           
(55/1,552) 
Marked increasing 
reports; Male gender 
and a history of 
polydrug use were risk 
factors 
ADR reports 
relating to 
pregabalin 
04/2008-
08/2012 
 Surveys 
The surveys identified were questionnaire-based and self-report undertaken in the US 
and UK (Table 2).  Three of the four survey studies recruited the patients diagnosed 
with substance abuse disorders from related clinics and centres, and then to see how 
many of them had drug misuse of gabapentinoids.  The sample size was around 100-
200 in the three studies and the gabapentinoids misuse rate of patients with substance 
abuse disorders was around 10% to 20% (32-34).  All three studies found the opioid 
addicted population were more likely to get gabapentin and pregabalin abuse.  The last 
study recruited the sample from a panel with unclear information about whether this 
panel was a general population sample or consisted of patients with any specific 
disease(s) (35). 
Generally the surveys included in the study were poor quality studies.  The 
questionnaire in the study conducted by Baird et al (32) had only nine questions, and 
the design was not comprehensive enough.  The questions were designed too briefly, 
and lacked the information of demographic characteristics, health conditions and 
disease history.  The study sample selected by Bastiaens et al (33) was from the 
community correctional centre’s treatment programme, which could be seriously 
biased because the sample is likely to have higher risk of substance abuse than the 
general population.  The study by Wilens et al (34) was of relatively higher quality 
according to the quality assessment, but this study was not specifically designed to 
investigate gabapentin or pregabalin misuse.  This study examined misuse of several 
medications among opioid dependent patients and did not focus on gabapentin or 
pregabalin.  These surveys cannot show the prevalence of gabapentin or pregabalin 
misuse, but can give a clue as to the possible association of the misuse of 
gabapentin/pregabalin and opioid prescriptions.  Kapil et al (35) were in collaboration 
with a global market research company.  A sample size of 1500 was chosen from panel 
members of the research company.  But more details of the panel, how the sample was 
chosen, and the definition of misuse were not given.  The age of the sample did not 
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follow a normal distribution.  There were 38 of 1500 participants reported to have 
lifetime misuse of GABA-analogue.  As well as the prevalence of gabapentin and 
pregabalin, this study also identified the source of misuse.  The supply was obtained 
mainly from health services, family or acquaintances, and also some were from the 
internet and outside UK.  
  
Table 2.  Summary of gabapentinoid misuse survey studies 
  
  
Study Sample Recruitment Rate Main findings 
Baird                  
2013                                     
Scotland (32) 
n=129 From six substance misuse clinics in 
Lothian region of Scotland 
ever used non-
prescribed 
gabapentinoids:              
22% (29/129)                                                        
Gabapentinoid 
abuse alongside 
with methadone 
11/2011-
01/2012 
Bastiaens                  
2016                                     
US (33) 
n=250 Patients with substance use disorder 
from community correctional centre 
non-medical use of 
gabapentin:                    
16% (41/250) 
Gabapentin abuse 
appears specific to 
an opioid addicted 
population 
 
Wilens                             
2015                               
US (34) 
n=196 Admissions to a public detoxification 
programme in Massachusetts, Bay 
Cove Human Services 
22% for gabapentin                          
7% for pregabalin                                                            
(of 162 opioid 
dependent 
patients)    
High levels of 
medication misuse
of both controlled 
and non-controlled 
agents 
05/2013-
08/2013 
Kapil                                          
2013                                                 
UK (35) 
n=1,500 UK panel members of a global market 
research company, aged 16 - 59. 
Lifetime prevalence 
of misuse of 
gabapentin: 1.1% 
(17/1,500);                                                      
pregabalin: 0.5% 
(8/1,500) 
Appreciable misuse 
of baclofen, 
gabapentin and 
pregabalin in the
UK.  The majority 
of misuse was from 
illegal sources 
 
  
 Cohort studies 
The summary of the two cohort studies is shown in Table 3.  One of the two cohort 
studies was editorial (36) and provided limited details of the methodology and results.  
A big increase of proportion of using gabapentin specifically to “get high” was reported 
from a cohort of 503 adults in Appalachian Kentucky.  However, this study was not 
originally designed for examining the misuse of gabapentin.  Thus, the recruitment of 
the study population and the indicators analysed in the study were not comprehensive 
for identifying the prevalence and factors of gabapentin misuse.   
Paulozzi et al (37) investigated the opioid analgesics medication for patients with a 
diagnosis of substance abuse.  In the study, a cohort of 1.85 million adults was 
examined and the follow-up period was divided to “Pre-abuse period”, “Abuse period” 
and “Post-abuse period”.  The participants in pre-abuse period were prescribed an 
opioid without diagnosis of substance abuse.  In the abuse period, 9,009 (0.49% of the 
total population) were patients diagnosed with substance abuse.  Then the outcomes 
were compared between participants diagnosed with substance abuse and not 
diagnosed in post-abuse period.  Each period was half a year.  In the study, patients 
with substance abuse were more likely to be prescribed gabapentin during the abuse 
period, but the number of prescriptions decreased in the post-abuse period among the 
patients with substance abuse.  
  
 
 
                  Table 3.  Summary of gabapentinoid misuse in cohort studies 
 
 
 
 
                          
                      
 
 
 
Study Cohort Recruitment Odds Ratio Main findings 
Paulozzi                                     
2016                                             
US (37) 
n=1,850,129 People with 
employer-sponsored 
insurance from a 
commercial claims 
and encounters 
database 
1.32 (95% CI: 
1.24-1.40) for 
abuse period;                          
0.84 (95% CI: 
0.80-0.89) for 
post-abuse 
period 
Gabapentin prescribing 
to patients dropped 
after diagnosed with 
abuse, while opioid 
prescribing changed 
little 
opioid users without 
abuse diagnoses 
aged 18-64 
01/2010-06/2011 
Smith                                                      
2014                                                        
US (36) 
n=503 Participants in a 
study of social 
networks and 
infectious disease 
risk in Appalachian 
Kentucky 
 Potential factors: 
female gender and co-
prescription of 
gabapentin and opioid                              
patients of opioid 
misuse 
 
11/2008-09/2010  
  *CI, confidence interval                                              
 Systematic review studies 
A review of misuse potential of pregabalin was conducted by Canadian Agency for 
Drugs and Technologies in Health (CADTH) (38).  This study was not published in a 
journal but was found in the website of CADTH.  There were 216 citations identified 
from the initial search and finally 7 of them were included in the study, including three 
case reports and two cross-over randomised controlled trials with a small sample of 15 
and 16.  The lack of high quality studies in the review by CADTH might be due to a 
limited search strategy, as the review did not show the terms and details of the search.  
The review was conducted in 2012, whereas most good quality studies identified in my 
systematic review were quite new studies published in 2015 and 2016. 
Schjerning et al (39) conducted a review in 2014 using only one word, “pregabalin”, as 
the term used for the search, so a large number of citations were found from the initial 
search.  But finally only 13 epidemiology studies were included.  Compared with my 
study, my study searched more databases, and used more accurate the terms for 
searching.  Fewer citations were identified from initial search, but my final included 
studies covered the results from this review.  More irrelevant searching results meant 
more extra work for the study selection.  This review identified not only epidemiology 
studies, but also preclinical, clinical studies and case reports.  To summarise from all 
types of studies, there was a significant abuse potential of pregabalin, especially for 
substance abuse patients.  Also, Smith et al (25) found gabapentin is being misused 
internationally, especially among patients with opioid abuse. 
  
 
               Table 4.  Summary of gabapentinoid misuse in systematic review studies 
 
  
Study Research question Searched databases Study selection Main findings 
Smith             
2016                                             
US(25) 
Misuse, abuse and 
diversion of
gabapentin 
PubMed, Web of 
Science, CINAHL, 
PsycINFO, Cochrane 
31, including 11 
epidemiology 
studies 
Gabapentin is being 
misused 
internationally, with 
higher risk among 
patients who abuse 
opioid 
Schjerning                                                                         
2016                                          
Denmark(39) 
The abuse potential 
of pregabalin 
PubMed, Embase, 
European Medicine 
Agency (EMA), the 
US Food and Drug 
Administration (FDA) 
13 epidemiology 
studies 
The preclinical, clinical 
and epidemiology 
evidence suggested the 
abuse potential of 
pregabalin, especially in 
people with substance 
abuse disorder 
CADTH                                                      
2012                                                        
Canada(38) 
Clinical evidence for
abuse and misuse
potential of 
pregabalin 
PubMed, Ovid 
Embase, Ovid 
PshycINFO, 
Cochrane, CRD 
7, including 3 
case reports and 
2 randomised 
controlled trials 
Pregabalin was 
reported to have low 
potential of abuse, but 
a history of drug 
addiction might play a 
role in the reward 
effect of pregabalin 
 2.3.3 Quality assessment 
The assessment of the quality of the four types of studies are shown in Tables 5-8.  
Only seven studies were relatively high quality studies and other studies had obvious 
limitations.  None of the reviews assessed the quality of included citations.  The 
questionnaires for the survey studies were designed too simply so that the data 
obtained had very limited information.  The description of recruitment and the analysis 
of the sample size of the surveys were not given in detail, and the population for the 
recruitment were biased, so the sample was not very representative of the general 
population.  Overall, the descriptive studies of large database analyses were of higher 
quality.
  
 
 
Table 5.  Quality assessment of observational studies of a large database analysis 
Assessment questions Chiappini Asomaning Schjerning Bossard Boden Gahr 
1 Was the research question or objective in this paper clearly stated? Y Y Y Y Y Y 
2 Was the study population clearly specified and defined? Y Y Y Y Y Y 
3 Were inclusion and exclusion criteria for recruitment described in 
detail? 
Y Y Y Y Y Y 
4 Were objective, standard criteria used for measurement of condition? Y Y Y Y Y Y 
5 
For exposures that can vary in amount or level, did the study examine 
different levels of the exposure as related to the outcome (e.g., 
categories of exposure, or exposure measured as continuous variable)? 
NA N N NA N NA 
6 Were the exposure measures (independent variables) clearly defined, 
valid, reliable, and implemented consistently across all study 
participants? 
Y Y Y Y Y Y 
7 Were the outcome measures (dependent variables) clearly defined, 
valid, reliable, and implemented consistently across all study 
participants? 
Y Y Y Y Y Y 
8 Was appropriate statistical analysis used? Y Y Y Y Y Y 
9 Were confounding factors identified? NA NA NA NA NA NA 
10 Were strategies to deal with confounding factors stated? NA NA NA NA NA NA 
Overall quality rating H L H H H M 
*Y, Yes; N, No; H, high; M, moderate; L, low; C, cannot determine; NA, not applicable; NR, not reported 
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 Table 6.  Quality assessment of survey studies 
 
                    
                   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment questions Kapil Wilens Bastiaens Baird 
1 Questionnaire M M L L 
2 Sampling M M L M 
3 Data collection NR H M M 
4 Data management M H L M 
5 Data analysis M H L L 
6 Reporting M H L L 
Overall quality rating L M L L 
*H, high; M, moderate; L, low; C, cannot determine; NA, not applicable; NR, not reported 
The details of the assessment are shown in Appendix 6 
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Table 7.  Quality assessment of observational studies of cohort studies 
Assessment questions Smith Paulozzi 
1 Was the research question or objective in this paper 
clearly stated? 
Y Y 
2 Was the study population clearly specified and 
defined? 
Y Y 
3 Were the subjects selected or recruited in an 
acceptable way and from the same population? 
Y Y 
4 Was a sample size justification, power description, or 
variance and effect estimates provided? 
N Y 
5 Was the timeframe sufficient so that one could 
reasonably expect to see an association between 
exposure and outcome if it existed? 
Y Y 
6 Were the exposure measures (independent variables) 
clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Y Y 
7 Were the outcome measures (dependent variables) 
clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
N Y 
8 Was the follow up of subjects complete enough? If 
not, were the reasons to loss to follow-up described 
and explored? 
Y Y 
9 Was appropriate statistical analysis used? Y Y 
10 Were key potential confounding variables measured 
and adjusted statistically for their impact on the 
relationship between exposure(s) and outcome(s)? 
N Y 
Overall quality rating L H 
*Y, Yes; N, No; H, high; M, moderate; L, low; C, cannot determine; NA, not 
applicable; NR, not reported 
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                               Table 8.  Quality assessment of observational studies of systematic review studies 
Assessment questions Smith Schjerning CADTH 
1 Did the review address a clearly focused question? Y Y Y 
2 Did the authors look for the right type of papers? Y Y Y 
3 Do you think all the important, relevant studies were included? Y Y N 
4 
Did the review’s authors do enough to assess the quality of the 
included studies? 
N N N 
5 
If the results of the review have been combined, was it reasonable 
to do so? 
NA NA NA 
6 
Were the overall results of the review reported and summarised 
properly? 
Y Y Y 
7 Were the results precise with confidence intervals? NA NA NA 
8 Can the results be applied to the local population? Y Y Y 
9 Were all important outcomes considered? Y Y N 
10 Are the benefits worth the harms and costs? Y Y Y 
Overall quality rating H H L 
*Y, Yes; N, No; H, high; M, moderate; L, low; C, cannot determine; NA, 
not applicable; NR, not reported 
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2.4 Discussion 
Gabapentin and pregabalin both have similar structure as the neurotransmitter 
gamma-aminobutyric acid (GABA) and interact with calcium channels in the central 
nervous system, and are commonly used to treat neuropathic pain.  Taking a large 
amount of gabapentin or pregabalin in a short time may lead to side effects, 
including feeling dizzy or sleepy, seeing double, slurring your words, diarrhoea 
confused or agitated, seizures and passing out (40).  Generally the medication for 
neuropathic pain is used long-term and the patients need take gabapentinoids for 
several months to years.  Some patients were reported to get addicted to 
pregabalin or gabapentin after the long-time intake and have withdrawal symptoms 
after stopping taking the medicine (24, 41). 
But there are some slight differences between the two drugs (42).  Gabapentin is 
used for treating migraine occasionally, while pregabalin is used for treating 
anxiety.  Pregabalin is considered to have a higher risk of getting abused than 
gabapentin.  Pregabalin was considered to potentially cause addiction and all the 
included observational studies of a large database analysis examined the misuse of 
pregabalin.  Only one of these six studies also examined the misuse of gabapentin 
and found the misuse reports of gabapentin were less (27).  However, the included 
survey studies suggested gabapentin, the medicine considered to cause little 
addiction or abuse before, might be used excessively for non-medical purposes as 
well.  The majority of previous studies investigated the gabapentin or pregabalin 
separately, while actually gabapentin and pregabalin were misused and prescribed 
together for some people.  It is more comprehensive to examine both gabapentin 
and pregabalin.   
This study systematically searched and selected the current citations of misuse of 
both gabapentin and pregabalin in population.  The overall evidence shows a 
potential misuse of gabapentinoids, with a growing number of both prescription of 
gabapentinoids and misuse reports internationally.  From the six observational 
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studies of large database analyses, the misuse prevalence ranges from 1.0% to 9.6% 
among pregabalin users and the prevalence for gabapentin misuse was 4.8% (27).  
More than 16% patients with substance abuse disorder had ever been prescribed 
gabapentin (33) and 7% had been prescribed pregabalin reported from survey 
studies (34).   
The identification of drug misuse in these studies largely depended on the system 
used for each database and how the data were collected.  So the definitions of 
misuse were quite different.  The Medical Dictionary for Adverse Drug Reactions 
(ADR) was used for the dataset from European Medicines Agency (EMA) (27) and 
French Pharmacovigilance Database (FPVD) (28), and the Medical Dictionary for 
Regulatory Activities was used for German Federal Institute for Drugs and Medical 
Devices (BfArM) (29).  Other studies identified overdose of over 600 mg per day 
based on the guidebook for pregabalin, and combined with codes: READ codes, 
Anatomical Therapeutic Chemical (ATC) codes, and the 10th version of International 
Classification of Diseases (ICD-10) (22, 30, 31).  The different definitions of “misuse” 
made it hard to combine the prevalence from these studies directly, and made the 
comparison of these studies more difficult.  And thus, the narrative review was 
used in this systematic review to summary the findings and prevalence of the 
misuse.  Some studies also examined the factors associated with overdose and 
misuse of gabapentin and pregabalin.  A history of substance abuse disorder was 
identified as a potential factor and gender was also found to have an effect on the 
misuse.  The cohort in Appalachian Kentucky showed more reports of gabapentin 
misuse among females (36).  Chiappaini et al (27) found more adverse drug reaction 
(ADR) reports of misuse, abuse and dependence from females in EV database as 
well.  In this study, overall ADR reports from females were more than three times of 
the reports from males.  On the contrary, the Danish (31), Swedish (30) and German 
(29) studies concluded that male gender was associated with higher risks of 
overdose.  In the study from Sweden, it suggested there was a 40% (95% CI: 31% – 
49%) (CI, confidence interval) higher risk of getting overdose of pregabalin among 
males than females (30).   
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Many studies suggested that the patients with a history of substance abuse 
disorder, especially opioid use disorder, were more likely to misuse gabapentin or 
pregabalin (33, 43).  In the Swedish study, it was 41% (95% CI: 31% – 52%) more 
likely to get overdose of pregabalin of patients ever diagnosed with substance 
misuse (30).  A history of polydrug use was identified as a potential factor for the 
misuse of pregabalin in the German study (29).  Most adverse drug reaction reports 
of misuse, abuse and dependence of gabapentin and pregabalin were combined 
with opioids from EV database (27).  Prescription of antipsychotic drugs and 
benzodiazepines was associated with overdose of pregabalin from the Danish study 
(31).  Prescribed methadone was identified to be associated with gabapentinoid 
abuse in the survey conducted in Scotland (32).  The surveys conducted by 
Bastiaens et al (33) and Wilens et al (34) found more than 20% patients with an 
opioid use disorder had ever used gabapentin for non-medical purpose or in 
overdose.  In the previous 30-days use of some opioids in a cohort increased 18.4% 
(95% CI: 4.3% - 33.1%) and 21.0% (95% CI: 7.1% - 35.7%) among gabapentin users, 
respectively (36).  It was reported that there has been a significant increase in the 
number of opioid prescriptions in the past few decades as well (44).  With more 
patients receiving high doses of opioids for long-term use, the morbidity of chronic 
pain remain high.   
Other factors associated with gabapentinoid misuse, like age and income, were 
examined in some studies.  However, due to very limited factors taken into 
consideration, no confounding factors were controlled in these studies, and the 
findings arising from these studies might be biased.  So it is not clear about the 
effect of these factors on the misuse and abuse of gabapentin and pregabalin. 
In summary, we could not confirm a clear conclusion based on the review.  As 
mentioned in the results, many of the studies had obvious limitations and were not 
very high quality studies.  In spite of the limitations of the design, data and analysis 
of the studies, the conflicts of interest of some studies would also weaken the 
power the study.   
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These studies had some connection with commercial pharmaceutical companies 
like Pfizer, Lundbeck, Orexo, Shire, etc.  It is unknown if the results from these 
studies are reliable enough.  For example, all the authors of the study examining 
the THIN primary care database were employed by Pfizer, and the study was 
funded by Pfizer (22).  It is suspicious that this study produced findings that were 
inconsistent with other studies, in that they found very small percentage of patients 
having pregabalin overdose and a history of substance abuse was not a potential 
factor for the misuse.  In addition, the first author of the Danish study and the 
systematic review of pregabalin abuse received speakers honoraria from Lundbeck, 
and the corresponding author received research grants from Pfizer and Lundbeck 
(31).  Also, the first author of the survey study in Massachusetts received research 
support from several pharmaceutical companies in the previous three years (34).  
Two authors of the letter of a cohort study reported to have some financial 
relationships with commercial companies (36).  The authors of the systematic 
review of gabapentin misuse were involved with some pharmaceutical companies 
including Pfizer (25).  Besides, the Swedish data linkage study was developed from 
another project with Pfizer as one of the funding sponsors, but they declared that 
this study was independent from the project and Pfizer did not affect the study 
(30).   
In all, seven of the fifteen citations reported no conflict of interest and the rest had 
more or less relationships with commercial pharmaceutical companies.  Among the 
seven studies without any conflict of interest, only three of them were marked as 
high quality studies in the quality assessment.   
This study has some strengths and is more comprehensive than the previous 
related reviews.  Unlike the previous review that missed the quality assessment of 
included studies, this study assessed the quality of each study, and analysed the 
pitfalls.  The tools used for the quality assessment were not simply taken from any 
existing tools, but modified from several commonly used tools according to the 
characteristics of each study type.  The quality assessment of current evidence 
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revealed the lack of high quality studies investigating the misuse of gabapentin and 
pregabalin.   
As well as the quality assessment, the search process was well-controlled in the 
study.  The initial search result was quite focused on the research question, so that 
less work for the study selection and thus fewer errors would be made.  This 
resulted from the exploration of search terms before the search.  MeSH terms in 
combination with free text were used to make the search more efficient.  The 
checking of reference lists suggested the good quality of the search, in that only 
one citation meeting the inclusion criteria was missed from my search and 
selection. 
However, this study also has some limitations.  After the quality assessment, the 
low quality studies were not excluded, and also the studies having some 
relationships with commercial pharmaceutical companies remained.  This might 
decrease the power of the conclusion summarised from these studies.  But this is 
due to the very limited amount of existing studies of the misuse of gabapentinoids.  
Gabapentin and pregabalin were introduced to the market less than 25 years ago, 
and people realised the possibility of getting dependence and abuse of the 
medicine just a few years ago.  So it is natural that limited studies investigating the 
misuse of gabapentinoid and more studies with a high quality are needed to 
examine the misuse of gabapentinoids in the population.  All the studies identified 
from the search and included after study selection were presented, but the 
conclusions were drawn from the high quality ones.  According to the limited 
research, the overall evidence showed a rising trend of misuse of gabapentin and 
pregabalin internationally.   
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3   Bridging from systematic view to data analysis: 
factors associated with co-prescription of 
gabapentinoids and opioids 
The systematic review of the misuse of gabapentin and pregabalin in the population 
found a rising trend of misuse with a growing number of prescriptions, especially 
among patients with a history of substance abuse disorder.  It also suggested that 
people who were opioid users were at a higher risk of being misusers of 
gabapentinoids.  The quality assessment showed there were few studies of good 
quality, and that more high quality studies were needed in the future research.  
There is therefore an evidence gap regarding the misuse of gabapentin and 
pregabalin, with a focus on co-prescribed opioids.  
Some previous studies had investigated the safety and effects of using 
gabapentinoids and opioids together.  An interview study with heroin users 
suggested that the combination of heroin and pregabalin could increase the effects 
of heroin but also the risk of abuse (45).  In the respiration study from the same 
research group, pregabalin was found to have a respiratory depression effect when 
combined with morphine, and could further increase the risk of heroin fatalities.  In 
a survey study, over one quarter of patients addicted to opioids reported the 
misuse of gabapentin (33).  A post-mortem study showed that pregabalin had a 
potential to be abused and lead to death, especially in combination with opioids 
(46).  Grosshans et al found 12.1% of opioid addicted patients had urine specimen 
positive for pregabalin (47).  However, a separate study found that the combination 
of pregabalin and oxycodone did not increase the euphoric effect of the opioid (48).   
In all, the evidence on the combination gabapentinoids and opioids was limited, 
and the current research came from small study samples and case studies.  No 
study analysed a large population dataset to examine co-prescription of opioids and 
gabapentinoids.   
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The study reported here will address this evidence gap by conducting a data linkage 
analysis of the population of opioid users in Tayside and Fife, to examine the factors 
associated with co-prescribed opioids and gabapentinoids.  In this study, the 
demography profiles were linked with prescription data and other clinical data.  The 
association between health outcomes/service use and co-prescribed opioids and 
gabapentinoids will be examined after controlling for the potential confounding 
effects of socioeconomic factors.   
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4   Methods 
4.1 Data management 
4.1.1 Data source 
The datasets for this study were obtained from Health Information Centre (HIC) 
services, including the datasets of demography profile, prescription, cancer 
registration, deaths, Accident and Emergency (A&E) attendance, hospital admission 
and psychiatric admission.  Death data was collected in both years of 2012 and 
2013, and cancer registration data were collected to the end of 2013.  All other data 
were collected in 2012.  Opioid and gabapentinoid prescriptions could be issued at 
any time during 2012.  So in this study, a cross-sectional study was conducted for 
health service use (A&E attendance, repeated hospital admission, psychiatric 
admissions) and a cohort study for mortality.   
The datasets were linked by matching the Pro-CHI number.  The Community Health 
Index (CHI) is a unique number for each patient used in Scotland for health care 
purposes.  Pro-CHI is an anonymised CHI number created by the HIC Data Analyst 
before releasing the data with Pro-CHI numbers.  This study is part of 2183 Opioid 
Project and was funded by Chief Scientist Office (CSO) (Reference number: CZH-4-
429).  It received formal approval from NHS Tayside Research and Development. 
The original demography data were collected by HIC and included 68,120 cases of 
individual profiles of all patients who were prescribed an opioid by a General 
Practitioner (GP) in Tayside and Fife in 2012.  The data included Pro-CHI number, 
age, sex, the Scottish Index of Multiple Deprivation (SIMD) of health board, GP 
registration date, and some other health related variables.  The SIMD is an area-
based measurement of deprivation reflecting the socioeconomic level in Scotland 
(49).  In our study, it was presented in quintiles of five categories, from the most 
deprived (SIMD=1) to the least deprived (SIMD=5) (50).  Data were stored on a 
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secure server, accessible only by the HIC Data Analyst and the System 
Administrator.   
A total of 580,815 GP prescriptions of opioids and gabapentinoids from Tayside and 
Fife were obtained in 2012.  The medicines were identified by the guidance of 
prescribing, the British National Formulary (BNF) code of 4.7.1 (Non-opioid and 
compound preparation), 4.7.2 (Opioid analgesics), 4.7.4.1 (Treatment of acute 
migraine), 4.8.1 (Anti-epilepsy & Neuropathic pain) and 4.10.3 (Opioid 
dependence).   
Dataset reporting deaths, psychiatric admissions, cancer registrations, A&E 
attendances and hospital admission were mainly presented with the Pro-CHI and 
date of the event.  The mortality data were shown by a list of Pro-CHI numbers for 
those who died in 2012 and 2013, with the cause of death coded using ICD-10.  For 
psychiatric admission, the variable showed the Pro-CHIs of patients who were 
admitted to a psychiatric centre in 2012.   The data from cancer registration 
showed the diagnosis of cancer from 1980 until the end of 2013.  The variables in 
the A&E attendance dataset showed the date patients attended A&E and the 
reasons for attending.  The date patients were admitted to a hospital is recorded in 
the hospital admission data.  Both the A&E attendance and hospital admission data 
were collected until the end of 2012.  An overview of the datasets is shown in 
Figure 2. 
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Figure 2.  Overview of opioids prescribing data linkage for NHS Tayside 
& Fife (2012) for the study 
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4.1.2 Data cleaning and grouping 
Within the demography data, age is a continuous variable and calculated until the 
end of 2012.  A histogram of age with a normal curve was constructed to show the 
distribution of age.  It was then categorised into age groups, the intervals of which 
were based on the histogram.    
The prescriptions were recoded according to the effect intergradient, and drugs 
with the same ingredients were combined.  For example, co-codamol (paracetamol 
and codeine), co-codaprin (aspirin and codeine) and co-codamol with bulizine 
(paracetamol, buclizine and codeine) were combined with codeine phosphate and 
all coded as codeine.  The opioids were categorised into two groups based on the 
potency of the drug.  Codeine, dihydrocodeine and meptazinol were categorised as 
WEAK opioid, and others were categorised as STRONG.  The categorisation of 
Tramadol into the WEAK or STRONG potency groups and how it should be viewed in 
a clinical setting was discussed before undertaking any data analysis.  Though other 
researchers have placed it in either category (30, 51), we thought it should go in the 
STRONG opioid group, as in the BNF it is recommended for moderate to severe 
pain, not mild pain like codeine, and it is now a controlled drug as all of the other 
strong opioids are.   
The data relating to A&E attendance were extracted to present in two variables.  
One is, has the patient ever attended A&E for any reason in 2012, and the other is, 
has the patient ever attended A&E for specific causes potentially related to 
gabapentin and pregabalin (alcohol and/or substance misuse, 
collapse/fall/unresponsive, overdose and psychiatry).  For the hospital admission 
data, the variable of repeated admission to hospital was created based on the 
frequency of being admitted; two admissions or more were recoded as repeated 
hospital admissions. 
Considering that there could be a data extraction error from the original data 
obtained from HIC, the data was cleaned according to the requirements of 
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recruitment of the study population.  The demography data were cleaned by 
excluding duplicate cases first.  As the population for this study were adults living in 
Tayside and Fife in 2012, patients not from Tayside or Fife, those who had died 
before 2012, were younger than 18 in 2012, and those who had registered out of 
the GP health boards in Tayside and Fife before 2012 would be excluded.  For 
prescription data, all Pro-CHIs should have at least one opioid prescription; 
therefore the cases prescribed gabapentin or pregabalin ONLY would be excluded.  
For other datasets, the cases that did not meet the recruitment requirements 
would be automatically removed when merged with demography data by matching 
the Pro-CHIs.  
4.1.3 Data linkage 
In order to be linked with other datasets and convenient for data analysis, all the 
datasets were organised to present by each variable per column and one row per 
subject.  While the GP description data were not presented in the expected way.  It 
was originated in the form of cases of each prescription, with Pro-CHI, the drug 
name, prescribed date, and dose.  So actually several rows may have referred to 
one subject.  The data were organised to the form with single Pro-CHI as the cases 
and the drugs as variables with the count of prescriptions for each patient.  The 
package of Reshape2 in R software was used to complete this conversion.  The 
codes used in R software are shown below: 
> library (reshape2) 
> data1 <- melt (PrescriptionData, id.vars="Pro-CHI") 
> data2 <- dcast (data1, Pro-CHI~PrescriptionData$DrugCode, length) 
Then all the datasets were linked and merged together by matching the Pro-CHIs.  
Patients with incomplete information of demography or prescription were 
excluded.   
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4.2 Data analysis 
4.2.1 Descriptive analysis 
As the data was obtained for the 2183 Opioid Project, some variables in the whole 
data were irrelevant for this study, for example, the date when the person was 
diagnosed with diabetes.  There were in total 22 variables in the original 
demography data, with only the age, sex and health board SIMD relevant for this 
study.  The consistency of each gender and SIMD was analysed.  While undertaking 
the steps of data linkage by merging all the datasets, some cases were lost.  
However, the frequency and corresponding percentage were calculated before and 
after merging the data with the difference of the percentages of a category 
analysed and reported.   
The frequency of prescription was initially counted from prescription items.  
However, during the analysis of the prescribing data, a data collection problem was 
found, so I changed the way to count the frequency of prescriptions.  The collection 
problem was, for one prescription, there might be more than one prescription item 
with different doses.  For example, a prescription of 250 units of a drug was shown 
in two prescription items of 200 units and 50 units in one day.  Thus, the dates of 
prescription were counted as the frequency; in one day, more than one prescription 
item of the same medicine were counted as one valid prescription, to avoid double 
counting of dates resulting from different doses of the medicine.  The frequency of 
each drug prescribed by all the patients and the average frequency (𝑓)̅ of each drug 
prescribed per patient was calculated: 
𝑓̅ =
𝑓 
𝑛
                   (1) 
In the equation, 𝑓 is the total frequency of prescriptions for all patients of one 
drug; 𝑛 is the number of patients who were prescribed this drug.  Also, the 
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frequencies of different potency of drugs were calculated to see which were 
prescribed more, weak or strong opioids. 
4.2.2 Chi-square test 
The patients recruited in this study were prescribed at least one opioid in Tayside 
and Fife in 2012, and some were also prescribed gabapentin or pregabalin.  The 
health outcomes/service use of patients prescribed opioid only and both opioids 
and gabapentinoids were compared.  The health outcomes/service use included 
death, cancer, psychiatric admission, A&E attendance and hospital admission.  The 
binary variable of death had two categories of being alive or dead from the 
beginning of 2012 till the end of 2013.  The groups for hospital admissions were 
repeated admission to hospital (hospital admission frequency was twice or more 
times), or not repeated admission (hospital admission frequency was zero times or 
once).  The variable of psychiatric admissions was categorised into yes and no.  The 
A&E attendances were recoded into two variables: one was attended for any cause 
or not, the other one was attended for alcohol and/or substance misuse, 
collapse/fall/unresponsive, overdose and psychiatry or not.  For example, if a 
patient only attended A&E because of an allergy, then the variables of this patient 
were yes for “attended for any cause” and no for “attended for drug related cause”.  
All these health outcomes/service use were in 2012, except for the cancer and 
deaths.  For cancer, it was a diagnosis of cancer before the end of 2013 or not.   
Chi-square testing is a statistical method used to compare the proportions of 
categorical variables.  In this study, it was used to investigate the differences 
between the patients prescribed opioid only, and who were prescribed both opioids 
and gabapentinoids.  The null hypothesis (H0) was defined that there is no 
association of health outcomes/service use with being prescribed both opioids and 
gabapentinoids.  On the contrary, the alternative hypothesis (H1) was that health 
outcomes/service use were related with co-prescribing of opioids and 
gabapentinoids.   
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The Chi-square test was used to see if the difference was statistically significant and 
if the null hypothesis could be rejected or not.  The significance level was set as 5%, 
which means it is 5% likely that the null hypothesis is rejected but actually it is true.  
The Chi-square test in this study would show the relationships between the health 
outcomes/service use and the co-prescribing opioids and gabapentinoids.  If the 
difference between patients prescribed both opioids and gabapentinoids and 
patients prescribed opioids only is significant, then the health outcomes/service use 
might be the factor for the co-prescription.  But this association could be affected 
by confounding factors, so further regression analyses were required. 
4.2.3 Logistic regression 
Logistic regression is used to investigate the association between a dependent 
binary variable and one or more independent variables.  In this study, the variables 
of health outcomes/service use are binary.  Thus, logistic regression models were 
fitted to examine the association between the binary health outcomes/service use 
and demographic and prescriptive factors.  The dependent variable was each health 
outcomes/service use, and the independent variables were all categorical.  
Demographic factors such as age group, sex and deprivation were fitted in the 
models.  Cancer condition was fitted in the models as an independent binary 
variable.  A reference category was chosen from each categorical variable.  For 
SIMD and gender, the category with largest size would be considered as the 
normative group, and set as the reference category, to make other categories to 
compare with this group.  For other variables, as the older age, diagnosed with 
cancer and co-prescribing opioids and gabapentinoids are factors for the health 
outcomes/health services that we want to examine, the youngest age group, no 
cancer and prescribed opioid only were defined as reference group.  The fitted 
logistic regression model is shown below: 
𝐻𝑥 ~ 𝐴𝑔𝑒 𝑔𝑟𝑜𝑢𝑝 + 𝑆𝑒𝑥 + 𝑆𝐼𝑀𝐷 + 𝐶𝑎𝑛𝑐𝑒𝑟 + 𝐺𝑎𝑏𝑎𝑝𝑒𝑛𝑡𝑖𝑛𝑜𝑖𝑑      (2) 
where, 𝐻𝑥 is each health outcomes/service use.   
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The logistic regression models could be used for prediction, and this requires the 
model to be best fit.  Some factors would be examined to see if the model fits 
better with or without this variable.  However, because of the restriction of the 
data, the independent variables were very limited and the models were lacking in 
other potential confounding factors for which to be controlled.  In addition, the 
logistic regression used in this study was not for prediction, but to examine the 
relationships between the variables.  So we decided to keep all five available factors 
in.  Even if some of the factors were insignificant, this would not influence the 
overall findings from the regression.  The 95% confidence interval (CI) was 
calculated, which means it is 95% likely that the true value is within this interval.   
All the analyses in the study were conducted in SPSS 22.0 and R.   
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4.3 Ethics and permission 
This study was considered by the East of Scotland Research Ethics Service, who 
determined that ethical approval was not required as all data for this study were 
anonymised prior to being released to the researchers.  The Data User Agreement 
for the Safe Haven was signed by the author and supervisors.   
The server "Safe Haven" is used to protect data confidentiality.  In the Safe Haven IT 
environment, the users can get secure access to statistics software to undertake 
the analysis.  Data and any results from the analysis cannot be exported out of the 
server without approval by HIC administrators.   
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5   Results 
5.1 Data cleaning  
In the demography dataset, nineteen pairs of duplicate cases were identified in 
SPSS.  Given that the duplicates were small in number, each duplication was 
checked manually.  The duplicate pairs with paradoxical information were both 
excluded, for example the same Pro-CHI but different genders or SIMD.  One pair of 
duplicate cases had the same information apart from one year difference of age.  
Considering the age would be classified into age groups in the further analysis, and 
this minor difference would not change the age category, only one of the cases 
were excluded.  For other duplicate cases with the same main variables (Pro-CHI, 
age, gender, SIMD), the ones with the later date of GP registration and more 
complete information were retained.  So, twenty-three cases were excluded 
because of duplication.  There were 65,939 cases in the demography dataset after 
the cleaning. 
The study population of prescription dataset was patients in Tayside and Fife ever 
prescribed at least one opioid in 2012.  Thus, those who were prescribed 
gabapentin or pregabalin ONLY and no opioid, were excluded.  After the reshaping 
in R, eighty-five Pro-CHIs were removed in the GP prescription data, and the 
cleaned data had 63,340 subjects. 
The variables of health outcomes/service use were computed to be binary.  There 
were five outcome variables after the data management: death in 2012-2013, 
psychiatric admission in 2012, repeated hospital admission in 2012, A&E 
attendance for drug related causes in 2012, A&E attendance for any cause in 2012. 
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5.2 Data linkage 
The demography data (N=65,939) and prescription data (N=63,340) were merged in 
SPSS and the cases were matched by Pro-CHI.  There were 61,736 cases left after 
merging.  The health outcomes/service use data were linked into this merged 
dataset as dependent variables.  The following flow chart shows the process of data 
cleaning and linking (Figure 3).  The numbers on the arrows show how many 
subjects were merged into the final sample.  The patients with Pro-CHIs in only one 
of the cleaned demography and GP prescription data were automatically excluded 
when using the function of “merge files” in SPSS.        
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Figure 3.  Flow chart of data cleaning and data linkage of demography and clinical data in Tayside and Fife (2012) 
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5.3 Descriptive analysis 
The variable of age in the demography dataset was continuous, and the distribution 
of the age is shown in the histogram (Figure 4).  The curve of the age distribution 
was bell-shaped.  Given that patients younger than 18 years in 2012 were excluded 
in the data cleaning, the distribution was slightly skewed.  Overall, age almost 
followed a normal distribution.  The mean age was 58.28±0.07 years, which was 
close to the median age of 59 years.  The oldest age was 106 years and the 
interquartile range (IQR) was 45 years to 75 years.  The width of the interval of age 
groups was decided to be around 20 years, and the age was categorised into four 
groups (18-39, 40-59, 60-79, and 80-106 years). 
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Figure 4.  Histogram of age distribution of patients in Tayside and Fife 
prescribed at least one opioid in 2012
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Table 9.  Characteristics of demography of patients prescribed opioid in Tayside and Fife in 2012 
Characteristic 
Before merging  (n=65,939)   After merging (n=61,736) Percentage changed 
(%) Frequency Percentage (%)   Frequency Percentage (%) 
Gender         
 Female 39,581 60.0 
 37,043 60.0 <0.1  
 Male 26,358 40.0 
 24,693 40.0 <0.1  
Age     
  
  
 
18-39 years 11,592 17.6  10,749 17.4 -0.2  
 
40-59 years 21,723 32.9  20,662 33.5 0.5  
 
60-79 years 23,816 36.1  22,041 35.7 -0.4  
 
over 80 years 8,808 13.4  8,284 13.4 0.1  
Health board SIMD        
 
1 - most deprived 16,734 26.1  15,927 26.5 0.4  
 
2 14,367 22.4  13,609 22.7 0.3  
 
3 12,346 19.3  11,598 19.3 0.1  
 
4 11,053 17.2  10,161 16.9 -0.3  
  5 - least deprived 9,607 15.0   8,724 14.5 -0.5   
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After merging, there were over 8,000 patients categorised in the eldest age group 
(over 80 years), comprising 13.4% of the whole study sample, which was the 
smallest age group.  The largest group was the second eldest group (60-79 years), 
which represented 35.7% with over 22,000 cases.  The youngest group (18-39 
years) had approximately half the number of the patients in age group of 60-79 
years.  And the group of 40-59 years had 2.2% less than the percentage of the 
largest age group among overall study sample.  Females represented 60.0% of the 
whole study sample.  There were 26.5% patients resident in areas categorised as 
most deprived (SIMD=1).  In this study, fewer people lived in less deprived areas 
(Table 9). 
The merging of the cleaned demography dataset and the GP prescription dataset 
made the size of the combined dataset decrease from 65,939 to 61,736.  There 
were 4,203 profiles lost after the merging.  The differences of the percentages of 
each category before and after the merging were calculated to see if the loss of 
cases changed the distribution of the demographic characteristics.  It shows that 
the percentages of each group of age, sex and SIMD had only very tiny changes 
after merging.  There was no evidence to suggest that the lost 4,203 subjects came 
from a specific population; instead, these were random patients.  The influence of 
the merging on changing the distribution of demography of the population was 
little.   
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Figure 5.  Bar Chart of total frequency of each opioids and gabapentinoids prescribed to all patients in Tayside 
and Fife (2012)
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Among all the opioids, tramadol was prescribed the most to all patients, with over 
169,000 prescriptions in 2012 (Figure 5).  Two weak opioids, codeine and 
dihydrocodeine, were the second and third most prescribed.  The total number of 
prescriptions of dihydrocodeine was about one third of the number of prescriptions 
of tramadol.  There were around 168,000 prescriptions of weak opioids (codeine, 
dihydrocodeine and meptazinol), and almost 296,000 prescriptions of all strong 
opioids.  The majority of opioid prescriptions were of strong opioids.  Gabapentin 
was prescribed more than twice as much as pregabalin was.  Both gabapentinoids 
were prescribed more than 66,000 times among all patients in Tayside and Fife who 
also received an opioid prescription during 2012.
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Figure 6.  Average frequency of prescriptions per patient of each opioids and gabapentinoids in Tayside and Fife 
(2012)
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Papaveretum was prescribed the least in total among all the patients (Figure 5), 
while the average frequency of papaveretum among the patients who were 
prescribed this drug was the most (Figure 6).  Very few patients from Tayside and 
Fife were ever prescribed papaveretum in 2012, but each of them had 14 
prescriptions on average.  Tramadol and the weak opioids were prescribed on 
average less often than other opioids.  The mean prescription of tramadol was 4.68 
per patient who was ever prescribed tramadol in 2012.  Almost 48,000 patients 
were prescribed at least one strong opioid, which composed 77.71% of the whole 
study sample.  Among these 48,000 patients, they had 6.17 prescriptions of strong 
opioids on average.  There were 9,841 patients prescribed both opioids and 
gabapentinoids.  These patients had 6.72 prescriptions of gabapentin or pregabalin 
on average in 2012.  
65 
 
Table 10.  Comparison of health outcomes/service use in patients prescribed opioids only and both opioids and 
gabapentinoids in Tayside and Fife 
    Opioid only Opioid + GABA Total 
P-value* 
    (n=51,895) (n=9,841) (n=61,736) 
Deaths∆        
Live 47,119 90.80% 9086 92.33% 56,205 
<0.001  
Dead 4,776 9.20% 755 7.67% 5,531 
Psychiatric Admissions        
No 51,506 99.25% 9747 99.04% 61,253 
0.037  
Yes 389 0.75% 94 0.96% 483 
A&E  
      
 
Attended for drug related causesƗ 2,133 4.11% 432 4.39% 2,565 
0.204  
Not attended for drug related causesƗ 49,762 95.89% 9409 95.61% 59,171  
 
      
 
Attended for any cause 12,776 24.62% 2657 27.00% 15,433 
<0.001  
Not attended for any cause 39,119 75.38% 7184 73.00% 46,303 
Hospital Admissions        
Repeated (admitted twice or more) 9,439 18.19% 2280 23.17% 11,719 
<0.001  
Not repeated (admitted once or never) 42,456 81.81% 7561 76.83% 50,017 
Cancer∆  
     
  
No 43,987 84.76% 8405 85.41% 52,392 
0.104 
  Yes 7,908 15.24% 1436 14.59% 9,344 
*Significance of Chi-square test 
ƗDrug related causes include alcohol and/or substance misuse, collapse/fall/unresponsive, overdose and psychiatry  
∆Deaths were in the year of 2012 and 2013; cancer was first registered before the end of 2013; other health outcomes/service 
use were during 2012 
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5.4 Chi-square test 
The patients who were prescribed an opioid only and those who were prescribed 
both opioids and gabapentinoids were compared by their health outcomes/service 
use (Table 10).  An unexpected result was that patients who were co-prescribed 
opioids and gabapentinoids had a lower mortality, and the difference was 
significant on Chi-square testing.  However, the difference was not big and this 
result might be biased by other confounding factors.  Further analysis by logistic 
regression was undertaken to test for possible confounders.   
The rate of patients being admitted to hospitals repeatedly (twice or more) in 
patients co-prescribed opioids and gabapentinoids (23.17%) was significantly higher 
than the rate of repeated hospital admissions in patients prescribed opioids only 
(18.19%).  A similar significant difference was in the rates of A&E attendance for 
any cause in patients prescribed gabapentinoid (27.00%) or not (24.62%).  But the 
difference in the rate of A&E attendance for drug related causes (alcohol and/or 
substance misuse, collapse/fall/unresponsive, overdose and psychiatry) was not 
significant on Chi-square testing.  Psychiatric admission occurred in less than 1.00% 
of all the patients though the difference was significant (p=0.037).   
A diagnosis of cancer might be a confounding factor for prescribing opioids and 
gabapentinoids, as patients with cancer frequently need the prescriptions to relief 
the pain.  From the Chi-square test, the likelihood of a diagnosis of cancer was not 
significantly different between patients who were co-prescribed gabapentinoids 
and those who were not. 
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Figure 7. Health outcomes/service use rates in patients prescribed opioid only and both opioids and 
gabapentinoids stratified by sex in Tayside and Fife  
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Figure 8. Health outcomes/service use rates in patients prescribed opioid only and both opioids and 
gabapentinoids stratified by age in Tayside and Fife 
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Figure 9. Health outcomes/service use rates in patients prescribed opioid only and both opioids and 
gabapentinoids stratified by SIMD of health board in Tayside and Fife
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From the Chi-square testing, there were four health outcomes/service use factors 
that were significantly different between patients who were prescribed opioid and 
patients who were co-prescribed opioids and gabapentinoids: deaths, psychiatric 
admissions, repeated hospital admissions, and A&E attendance for any cause.  The 
comparison of the rates of these four outcome variables between patients co-
prescribed both opioids and gabapentinoids or not was stratified by sex, age and 
SIMD (Figure 7-9).  When stratified by age groups, we can see that it was only 
among patients aged over 80 years that a lower death rate among patients with co-
prescription was apparent (Figure 8), and this age group influenced the overall 
results of death rates (Table 10).  As older people are more likely to die, age could 
be considered as a possible confounding factor for the relationship between co-
prescription and death.   
As age increased, the attendance rate at A&E for any cause was U-shaped, the 
middle age groups attending less.  In every age category, patients with co-
prescription all had higher A&E attendance rate.  Similar to the trend with death 
rate, the likelihood of repeated admission increased with age.  Furthermore, 
patients who were co-prescribed opioids and gabapentinoids were more likely to 
experience repeated admission to hospital in each age group.  In contrast to the 
rising trend of death rate and repeated hospital admission rate, the psychiatric 
admission rates decreased with increasing age.  Except for the oldest age group 
(more than 80 years), patients receiving co-prescription were repeatedly admitted 
to hospital more in all age groups, but these differences were very tiny.   
Female patients represented 60% of the overall study sample, but males had a 
higher rate of health service use.  For psychiatric admissions, A&E attendance for 
any cause and repeated hospital admissions, patients with co-prescription of an 
opioid and a gabapentinoid had higher use of these health service in both genders.  
The differences among the five deprivation groups were small. 
 Table 11. Logistic regression of co-prescription of opioids and gabapentinoids associated with health outcomes/service use* in 
Tayside and Fife 
 Mortality Psychiatric admissions 
A&E attendance  
for any cause 
Repeated hospital 
admissions 
    OR (95% CI) P   OR (95% CI) P   OR (95% CI) P   OR (95% CI) P 
Co-prescription                
 Opioid only Reference group  Reference group  Reference group  Reference group 
 Both opioids & 
gabapentinoids 
1.01 (0.92-1.10) 0.91  1.25 (0.99-1.58) 0.07  1.19 (1.13-1.25) <0.01  1.49 (1.41-1.57) <0.01 
Age   <0.01    <0.01    <0.01    <0.01 
 18-39 years Reference group  Reference group  Reference group  Reference group 
 40-59 years 2.70 (2.18-3.34) <0.01  0.60 (0.48-0.76) <0.01  0.61 (0.58-0.65) <0.01  1.04 (0.97-1.12) 0.31 
 60-79 years 7.86 (6.41-9.64) <0.01  0.32 (0.25-0.42) <0.01  0.53 (0.50-0.56) <0.01  1.56 (1.45-1.67) <0.01 
 over 80 years 25.75 (20.97-31.65) <0.01  0.62 (0.46-0.85) <0.01  0.87 (0.82-0.93) <0.01  2.44 (2.26-2.64) <0.01 
Sex                
 Female Reference group  Reference group  Reference group  Reference group 
 Male 1.38 (1.29-1.46) <0.01  1.14 (0.94-1.37) 0.17  1.18 (1.14-1.23) <0.01  1.15 (1.10-1.20) <0.01 
Health Board SIMD   <0.01    0.08    <0.01    0.68 
 1-most deprived Reference group  Reference group  Reference group  Reference group 
 2 0.93 (0.84-1.02) 0.11  1.13 (0.89-1.44) 0.32  0.97 (0.92-1.02) 0.21  1.01 (0.95-1.07) 0.84 
 3 0.99 (0.90-1.09) 0.87  0.83 (0.63-1.10) 0.20  0.82 (0.78-0.87) <0.01  1.00 (0.94-1.07) 0.89 
 4 1.12 (1.02-1.24) 0.02  0.98 (0.74-1.30) 0.89  0.76 (0.71-0.80) <0.01  0.99 (0.92-1.05) 0.67 
 5-least deprived 1.04 (0.94-1.15) 0.47  0.74 (0.53-1.03) 0.08  0.76 (0.71-0.81) <0.01  0.96 (0.89-1.03) 0.24 
CancerƗ                
 No Reference group  Reference group  Reference group  Reference group 
  Yes 5.78 (5.42-6.15) <0.01   0.88 (0.65-1.18) 0.39   1.20 (1.14-1.27) <0.01   3.20 (3.05-3.37) <0.01 
*Deaths were in the year of 2012 and 2013; other health outcomes/service use were during 2012 
ƗCancer was first registered before the end of 2013 
CI, confidence interval 
 5.5 Logistic regression  
The association of co-prescribing of opioids and gabapentinoids and health 
outcomes/service use was examined by logistic regression, to account for any 
confounding effects (Table 11).  After controlling for confounding variables (age, sex, 
deprivation and cancer), co-prescription was no longer significantly associated with 
death.  The findings from the Chi-square test (Table 10) that a lower mortality was 
observed in patients prescribed both opioids and gabapentinoids, could be explained 
from the logistic regression, that the apparent association was caused by the 
confounders.  Among the variables fitted in the model, an older age and a diagnosis of 
cancer were the most important factors relating to death.  Compared with that in the 
youngest age group (18-39 years), the odds of people in the oldest age group (over 80 
years) increased to have died by about 25 times.  Also, no significant association was 
found in the rates of psychiatric admissions between those co-prescribed opioids and 
gabapentinoids and those prescribed opioids only, after accounting for confounders. 
Demographic factors, cancer and co-prescription of opioids and gabapentinoids had 
significant effects on the rate of attendance at A&E for any cause.  A higher 
socioeconomic class and older age were protective factors for attending A&E, while the 
effect of growing age on A&E attendance was not monotonic.  The odds of oldest age 
group (over 80 years) to attend A&E were higher than the odds of age groups between 
40 to 79 years, but lower compared to the odds of youngest age group (18-39 years).  
The odds of being repeatedly admitted to hospital was increased by 49% (95% CI: 41%-
57%) when the patients co-prescribed both opioids and gabapentinoids, compared 
with odds of those who were prescribed opioids only.  Male gender was a marker of 
higher risk of death and more health service use.   
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In all, after controlling the confounders of demographic factors and cancer, the co-
prescription of opioids and gabapentinoids was associated with A&E attendance (for 
any cause) and repeated hospital admissions.  
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6   Discussion 
For this study, the clinical datasets and demography dataset in Tayside and Fife were 
linked by identifying the unique Pro-CHI number of each patient.  There were 61,736 
adults prescribed at least one opioid in Tayside and Fife during 2012 recorded by the 
NHS, after cleaning and merging the datasets.    
From the descriptive analysis of the demography data, there were 26.5% classified as 
being registered in the most deprived health board, and there were more people living 
in the more deprived areas.  In our study, females represented 60% of the study 
sample, and the overall mean age of the study sample was 58.28 years.  In an 
observational drug utilisation study of patients prescribed pregabalin in UK (N=13,480), 
the median age of patients was 58 years, and female composed 59.4% of the study 
sample (22).  In a Swedish population study, 61.4% of the patients prescribed 
pregabalin were females (n =48,550) (30). The distribution pattern of demography is 
similar to that in our study.   
Among the 61,736 patients, there were 9,841 people prescribed more than 66,000 
prescriptions of gabapentinoids.  A total of around 168,000 prescriptions of weak 
opioids (codeine, dihydrocodeine and meptazinol), and almost 296,000 prescriptions of 
all strong opioids were prescribed in Tayside and Fife during 2012, and tramadol was 
prescribed the most often, with over 169,000 prescriptions.  With the analgesic effects, 
opioids are commonly used for treating different types of pain, including acute pain, 
cancer pain and chronic non-cancer pain (52).  Tramadol is considered to be safer and 
has a lower abuse potential than other strong opioids do, so it serves as an important 
alternative to other opioids (53).   
In some countries, there have been studies using gabapentinoids to treat the 
dependence on, and withdrawal from opioids (54, 55), and a combination of opioids 
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and gabapentinoids for treating neuropathic pain has also been investigated (56).  
However, opioids and gabapentinoids are not recommended to be prescribed together 
in the UK.  Both opioids and gabapentinoids are dangerous and have a potential for 
abuse (44, 57).  The misuse of gabapentin and pregabalin is related to opioid addiction 
(33, 43).  In the cohort study in Appalachian Kentucky, participants who were 
gabapentin users were more likely than non-users to be abusing opioids (36).  Lyndon 
et al found that co-prescription of opioids with gabapentinoids could increase the risk 
of acute overdose death (45).   
However, in our study, from the Chi-square test, the mortality of patients prescribed 
opioid only was significantly higher than the mortality of patients who were co-
prescribed both opioids and gabapentinoids (percentage differences=1.53%).  The 
result that co-prescription of gabapentinoids and opioids was related to lower 
mortality is not consistent with previous studies.  This could be biased by other factors.  
For example, age is very closely related to death.  Thus, logistic regression was 
conducted to control for potential confounding variables in the association between 
co-prescribed opioids and gabapentinoids and health outcomes/service.  The 
relationship between co-prescribed opioids and gabapentinoids and death was no 
longer significant after controlling for the demographic variables and cancer.  From the 
model, it was mainly older age and a diagnosis of cancer that were associated with 
higher mortality (Table 11).   
The drug use was reported to be associated with certain health service use (58).  As 
well as death, the association of co-prescription of opioids and gabapentinoids and 
health service use was also examined.  The Chi-square testing showed that the patients 
prescribed both opioids and gabapentinoids had significantly higher rates of psychiatric 
admissions, A&E attendance for any cause and repeated hospital admissions.  After 
controlling for the potential confounders of demography factors and cancer, A&E 
attendance for any cause and repeated hospital admissions were still associated with 
co-prescription.   
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A&E attendance could be seen as an indicator of adverse health condition. Patients 
with drug misuse commonly attend A&E for drug related causes.  It has been found 
that patients attending A&E with drug related morbidity were more likely to have a 
subsequent drug related death (59).  In our study, the relationship between co-
prescribed opioids and gabapentinoids and A&E attendance for drug related causes 
was not found to be significant, while the A&E attendance for any cause was observed 
to be associated with co-prescription.  This may result from inaccurate records, in that 
some drug-related attendances might have been miscoded.  In this study, the alcohol 
and/or substance misuse, collapse/fall/unresponsive, overdose and psychiatry were 
defined as drug related causes.  But there could be other reasons not listed here also 
drug-related, in an indirect way.  Comparing the two outcomes of A&E attendance, the 
A&E attendance for any cause is less specific, but a much more objective and 
measurable outcome than the attendance for these specific reasons. 
One of the main methods used for this study was data linkage.  Different datasets were 
linked together at an individual level by the unique Pro-CHI number.  By merging the 
data, the information available for each patient was richer, which allowed us to 
examine the different factors.  However, the merging could cause a loss of cases too.  
In this study, it was mainly the demography data and GP prescribing data which 
determined the final sample size, and other datasets were merged to add variables but 
would not influence the number of cases.  The demography dataset was cleaned first, 
with the removal of cases which did not meet the requirements of the recruitment and 
duplications.   
The cleaned demography dataset contains the profiles of adults in Tayside and Fife 
who were prescribed at least one opioid in 2012.  Ideally, the demography data could 
be perfectly connected with the prescription data.  However, there were 4,203 subjects 
in the cleaned demography dataset whose Pro-CHIs were not part of the GP 
prescribing dataset.  This might result from a data extraction error from HIC.  Some 
subjects were not prescribed any opioid in Tayside and Fife during 2012, but they were 
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mistakenly included in the raw demography dataset.  By removing these subjects the 
quality of the data was improved.   
However, it was possible that some patients were prescribed opioids that had been 
recorded in GP prescription data, but somehow were not included in the original 
demography data.  The distribution of the demography data might be biased by 
missing these cases.  For this study, the changes in percentages of each group of 
demographic variables were calculated, to see if after merging the pattern of the 
demography distribution changed.  It turned out that the changes were very small and 
there was no evidence to show the data were biased after merging.  So the loss of 
cases in the data linking process was not observed to change the demography 
distribution (Table 9).   
There are some strengths to the study.  First, the data linkage was used to combine the 
demographic profiles with prescription and clinical datasets, and this enlarged the data 
and had more information available.  Also the influence of data merging was examined 
to make sure the linkage did not bias the data distribution, as discussed above.   
Secondly, the datasets were well cleaned and managed before doing further data 
analysis (Figure 3).  Given that many variables were already binary variables, death, 
cancer, psychiatric admissions, other variables of health outcomes/service use were all 
recoded to be binary variables, in order to allow the logistic regression modelling.  The 
hospital admission data were provided as the dates and Pro-CHI numbers relating to 
admissions to hospitals.  Originally this was a continuous variable of the number of 
times the patients were admitted to hospital, but it was computed to a binary variable 
with the groups of repeated hospital admissions in 2012 and fewer than two 
admissions.  The indicator of repeated hospital admissions has been commonly used in 
studies of chronic diseases (60, 61), where it implies the poor health condition of the 
person, and also a burden on medical resources.  Age was classified into four age 
groups based on the distribution of age shown in the histogram (Figure 4).   
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Thirdly, the demographic variables (age, sex and SIMD) and cancer were fitted in the 
logistic regression model as potential confounders and explained the biased results 
from Chi-square test.  The demography is important for investigating the factors of 
diseases and health.  Some diseases may occur more in a particular age group, and 
morbidities of chronic diseases tend to increase with the age growing, and also more 
medication (62).  The health problems related to opioids and gabapentinoids are not 
reproductive, but males and females have different behaviours and habits.  
Socioeconomic status is also an important factor and people from different social class 
are exposed to different environments and social relationships.  In this study, 
socioeconomic status was measured by the health board SIMD.   
Cancer is another important potential confounding factor for the association between 
health outcomes/service use and co-prescription of opioids and gabapentinoids.  These 
medicines are also commonly prescribed for cancer patients, as moderate to severe 
pain is common in cancer, and difficult to treat (63, 64).  By fitting the factor of cancer 
in the logistic regression model, the potential effect of cancer on the prescription and 
health outcomes/service use was controlled.  
However, there are also some weaknesses to the study.  The data analyses in the study 
were restricted by the available data, and this is the main limitation of the study.  The 
datasets were restricted to patients prescribed opioids in Tayside and Fife in 2012, and 
some datasets were also from 2013.  Tayside and Fife are two small regions in 
Scotland, so compared with other national studies (27, 30, 37) using gabapentinoids 
and opioid prescription data, the sample size of this study was relatively small.  Also, in 
this study, prescription data on gabapentinoids were only available on opioid 
prescribed patients (n=9,841).  The prescription data on gabapentinoids for all the 
population in Tayside and Fife were not available.   
Apart from the limitation of study sample size, the variables of the factors and 
confounders of the co-prescribed opioids and gabapentinoids in the study were also 
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limited.  There were 22 variables in the original demography dataset.  However, some 
variables in the demography dataset were repeated.  For example, the anonymised 
date of birth and calculated age actually conveyed the same information. For SIMD, 
there were postcode SIMD based on the address of the patient, and health board SIMD 
based on the GP practice with which the patient was registered, and SIMD with 5 
categories and 10 categories.  Among these variables reflecting socioeconomic class, 
health board SIMD with 5 categories was chosen.  Also there were some variables that 
were considered irrelevant for answering the research question, such as care home 
type, date of diagnosis of diabetes.   
After excluding the repeated and irrelevant variables, only three demographic variables 
(age, sex, SIMD of health board) could be analysed as factors or potential confounders 
in the analysis.  All these three demographic variables were fitted in the model, as they 
are important factors in disease and health related studies.  As well as these three 
demographic variables, only the cancer registration could be included in the analysis as 
a potentially confounding variable.  A lack of more information on the health condition 
and history of diseases made the fitting of logistic regression modelling more difficult.  
There could be some other potential confounders (e.g. chronic diseases, smoking 
status, previous medical history, and family history) that biased the measured 
association between the health outcomes/service use and co-prescribed opioids and 
gabapentinoids, and these variable would have been included in the analysis if they 
had been available. 
In summary, A&E attendance for any cause and repeated hospital admissions were 
associated with co-prescribed opioids and gabapentinoids, after controlling for 
demographic factors and cancer.  This implies that the co-prescription of 
gabapentinoids and opioids is associated with an increased overall risk of injury and/or 
acute ill health.  Although further work of population-based studies with larger sample 
size and more comprehensive variables is needed to examine this in more detail, 
health service providers, prescribers and patients need to be aware of this risk, 
80 
 
avoiding co-prescription where possible and taking preventive steps to avoid these 
outcomes.  Consideration is currently being given to introducing restrictions to 
prescribing gabapentinoids (making it a controlled drug).  Until or unless these are in 
place, there should be education and awareness raising about this potential problem 
nationally. 
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7   Conclusions  
Overall evidence from published papers on the use and misuse of gabapentinoid 
prescribing found the rising trend of misuse internationally.  Patients with a history of 
substance abuse disorder were potentially more likely to misuse gabapentinoids, 
especially those patients with a history of opioid abuse.  It suggested the key needs and 
directions for further studies that population studies are needed to examine factors of 
gabapentinoid misuse, with a focus on opioid users. 
Followed by the systematic review, the database analysis study is so far the first study 
to examine the factors associated with co-prescribed opioids and gabapentinoids, to 
our knowledge.  A&E attendance for any cause and repeated hospital admissions were 
associated with co-prescribed opioids and gabapentinoids in logistic regression models, 
after controlling for demographic factors and cancer.  This implied that co-prescribed 
opioids and gabapentinoids could be potentially harmful, as a higher rate of the health 
service use suggested a worse health condition and greater burdens of medical 
resource use.  For future studies, prescription data relating to gabapentin and 
pregabalin from the whole population are needed. Data from a larger and more 
representative population with more potential confounding variables would have more 
power in examining the harm and factors of the use and misuse of gabapentinoids.   
 
  
82 
 
8   References 
1. Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain. 
2008;137(3):473-7. 
2. Ligon CO, Moloney RD, Greenwood-Van Meerveld B. Targeting Epigenetic 
Mechanisms for Chronic Pain: A Valid Approach for the Development of Novel 
Therapeutics. The Journal Of Pharmacology And Experimental Therapeutics. 
2016;357(1):84-93. 
3. Niikura K, Narita M, Butelman ER, Kreek MJ, Suzuki T. Neuropathic and chronic 
pain stimuli downregulate central μ - opioid and dopaminergic transmission. Trends in 
Pharmacological Sciences. 2010;31(7):299-305. 
4. Katzman MA, Pawluk EJ, Tsirgielis D, D'Ambrosio C, Anand L, Furtado M, et al. 
Beyond chronic pain: How best to treat psychological comorbidities. Journal of Family 
Practice. 2014;63(5):260-4. 
5. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain 
in Europe: prevalence, impact on daily life, and treatment. European Journal of Pain. 
2006;10(4):287-333. 
6. Fayaz A, Croft P, Langford R, Donaldson L, Jones G. Prevalence of chronic pain in 
the UK: a systematic review and meta-analysis of population studies. British Medical 
Journal open. 2016;6(6):e010364. 
7. Tauben D. Nonopioid Medications for Pain. Physical Medicine and 
Rehabilitation Clinics of North America. 2015;26(2):219-48. 
8. Lindsay L, Farrell C. Pharmacological management of neuropathic pain. 
Prescriber. 2015;26(9):13-8. 
9. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the 
nervous system to damage. Annual Review of Neuroscience. 2009;32:1-32. 
10. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular 
mechanisms of pain. Cell. 2009;139(2):267-84. 
83 
 
11. Dobecki DA, Schocket SM, Wallace MS. Update on pharmacotherapy guidelines 
for the treatment of neuropathic pain. Current Pain and Headache Reports. 
2006;10(3):185-90. 
12. Jones RCW, Lawson E, Backonja M. Managing Neuropathic Pain. Medical Clinics 
of North America. 2016;100(1):151-67. 
13. van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the 
general population: a systematic review of epidemiological studies. Pain. 
2014;155(4):654-62. 
14. O'Connor AB, Dworkin RH. Treatment of Neuropathic Pain: An Overview of 
Recent Guidelines. The American Journal of Medicine. 2009;122(10):S22-S32. 
15. Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin–Calcium 
channel α2-δ [Cavα2-δ] ligands. Pain. 2009;142(1-2):13-6. 
16. Finnerup NB, Jensen TS. Clinical use of pregabalin in the management of central 
neuropathic pain. Neuropsychiatric Disease and Treatment. 2007;3(6):885-91. 
17. Chen DT, Wynia MK, Moloney RM, Alexander GC. US physician knowledge of 
the FDA-approved indications and evidence base for commonly prescribed drugs: 
results of a national survey. Pharmacoepidemiology and drug safety. 
2009;18(11):1094-100. 
18. Schifano F. Misuse and abuse of pregabalin and gabapentin: Cause for concern? 
CNS Drugs. 2014;28(6):491-6. 
19. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: Evidence 
from randomized, placebo-controlled clinical trials. Clinical Therapeutics. 
2003;25(1):81-104. 
20. Mendlik MT, Uritsky TJ. Treatment of neuropathic pain. Current treatment 
options in neurology. 2015;17(12):50. 
21. Schug SA, Goddard C. Recent advances in the pharmacological management of 
acute and chronic pain. Annals Of Palliative Medicine. 2014;3(4):263-75. 
22. Asomaning K, Abramsky S, Liu Q, Zhou X, Sobel RE, Watt S. Pregabalin 
prescriptions in the United Kingdom: A drug utilisation study of the Health 
84 
 
Improvement Network (THIN) primary care database. International Journal of Clinical 
Practice. 2016;70(5):380-8. 
23. Berlin RK, Butler PM, Perloff MD. Gabapentin therapy in psychiatric disorders: A 
systematic review. Primary Care Companion to the Journal of Clinical Psychiatry. 
2015;17(5). 
24. Suardi NE, Preve M, Godio M, Bolla E, Colombo RA, Traber R. Misuse of 
pregabalin: Case series and literature review. European Psychiatry. 2016;33:S312. 
25. Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a 
systematic review. Addiction. 2016;111(7):1160-74. 
26. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
Statement: Guidelines for reporting observational studies. International Journal of 
Surgery. 2014;12(12):1495-9. 
27. Chiappini S, Schifano F. A Decade of Gabapentinoid Misuse: An Analysis of the 
European Medicines Agency's 'Suspected Adverse Drug Reactions' Database. CNS 
Drugs. 2016;30(7):647-54. 
28. Bossard JB, Ponte C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. 
Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of 
Pregabalin in the French Pharmacovigilance Database. Clinical Drug Investigation. 
2016;36(9):735-42. 
29. Gahr M, Freudenmann R, Hiemke C, Kölle M, Schönfeldt-Lecuona C. Pregabalin 
abuse and dependence in Germany: results from a database query. European Journal 
of Clinical Pharmacology. 2013;69(6):1335-42. 
30. Boden R, Wettermark B, Brandt L, Kieler H. Factors associated with pregabalin 
dispensing at higher than the approved maximum dose. European Journal of Clinical 
Pharmacology. 2014;70(2):197-204. 
31. Schjerning O, Pottegard A, Damkier P, Rosenzweig M, Nielsen J. Use of 
Pregabalin - A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus 
on Abuse Potential. Pharmacopsychiatry. 2016;49(4):155-61. 
85 
 
32. Baird CRW, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the 
effect of methadone: A survey among substance misusers. European Addiction 
Research. 2014;20(3):115-8. 
33. Bastiaens L, Galus J, Mazur C. Abuse of Gabapentin is Associated with Opioid 
Addiction. Psychiatric Quarterly. 2016;87(4):763-7. 
34. Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription 
medication misuse among opioid dependent patients seeking inpatient detoxification. 
American Journal on Addictions. 2015;24(2):173-7. 
35. Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the gamma-
aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. British 
Journal of Clinical Pharmacology. 2014;78(1):190-1. 
36. Smith RV, Lofwall MR, Havens JR. Abuse and diversion of gabapentin among 
nonmedical prescription opioid users in Appalachian Kentucky. American Journal of 
Psychiatry. 2015;172(5):487-8. 
37. Paulozzi LJ, Zhou C, Jones CM, Xu L, Florence CS. Changes in the medical 
management of patients on opioid analgesics following a diagnosis of substance abuse. 
Pharmacoepidemiology and Drug Safety. 2016;25(5):545-52. 
38. CADTH. Abuse and Misuse Potential of Pregabalin: A Review of the Clinical 
Evidence 2012. Available from: https://www.cadth.ca/abuse-and-misuse-potential-
pregabalin-review-clinical-evidence [Accessed 23rd Nov 2016]. 
39. Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse Potential 
of Pregabalin: A Systematic Review. CNS Drugs. 2016;30(1):9-25. 
40. Mendlik MT, Uritsky TJ. Treatment of Neuropathic Pain. Current Treatment 
Options in Neurology. 2015;17 (12) (no pagination)(50). 
41. Tcheremissine OV, Bestha DP. Gabapentin abuse in a patient with comorbid 
mood and substance use disorders. Innovations in Clinical Neuroscience. 2016;13(7-
8):13-4. 
42. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A 
comparison of the pharmacokinetics and pharmacodynamics of pregabalin and 
gabapentin. Clinical pharmacokinetics. 2010;49(10):661-9. 
86 
 
43. McNamara S, Stokes S, Kilduff R, Shine A. Pregabalin Abuse amongst Opioid 
Substitution Treatment Patients. Irish Medical Journal. 2015;108(10):309-10. 
44. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the 
United States: concerns and strategies. Drug and alcohol dependence. 2006;81(2):103-
7. 
45. Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, et al. Risk to heroin users 
of polydrug use of pregabalin or gabapentin. Addiction. 2017;112(9):1580-9. 
46. Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and 
gabapentin abuse by postmortem toxicology. Forensic Science International. 
2014;241:1-6. 
47. Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, 
et al. Pregabalin abuse among opiate addicted patients. European Journal of Clinical 
Pharmacology. 2013;69(12):2021-5. 
48. Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological 
effects of pregabalin alone and in combination with oxycodone in healthy volunteers. 
Pharmacology Biochemistry and Behavior. 2012;100(3):560-5. 
49. Payne R, Abel G. UK indices of multiple deprivation - A way to make 
comparisons across constituent countries easier2012. 22-37 p. 
50. ISD Scotland - GDP Support - Deprivation. Available from: 
http://www.isdscotland.org/Products-and-Services/GPD-Support/Deprivation/ 
[Accessed 1st Sep 2017]. 
51. Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 
1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large 
geographical population in Scotland. European Journal of Pain. 2015;19(1):59-66. 
52. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: 
systematic review of efficacy and safety. Pain. 2004;112(3):372-80. 
53. Grond S, Sablotzki A. Clinical Pharmacology of Tramadol. Clinical 
Pharmacokinetics. 2004;43(13):879-923. 
87 
 
54. Kheirabadi GR, Ranjkesh M, Maracy MR, Salehi M. Effect of add-on gabapentin 
on opioid withdrawal symptoms in opium-dependent patients. Addiction. 
2008;103(9):1495-9. 
55. Ziaaddini H, Ziaaddini A, Asghari N, Nakhaee N, Eslami M. Trial of tramadol plus 
gabapentin for opioid detoxification. Iranian Red Crescent Medical Journal. 
2015;17(1):1-5. 
56. Vorobeychik Y, Gordin V, Mao J, Chen L. Combination Therapy for Neuropathic 
Pain. CNS Drugs. 2011;25(12):1023-34. 
57. Mutschler J, Gastberger S, Baumgartner MR, Grosshans M, Seifritz E, Quednow 
BB, et al. Pregabalin Use among Opioid-Addicted patients in Switzerland. Journal of 
Clinical Psychiatry. 2016;77(9):1202-3. 
58. McIntosh J, Bloor M, Robertson M. The health benefits of reductions in 
individuals' use of illegal drugs. Journal of Substance use. 2008;13(4):247-54. 
59. Ryan JM, Spronken I. Drug related deaths in the community: A preventive role 
for accident and emergency departments? Emergency Medicine Journal. 
2000;17(4):272-3. 
60. Zhang M, Holman CDAJ, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. 
Comorbidity and repeat admission to hospital for adverse drug reactions in older 
adults: retrospective cohort study. British Medical Journal. 2009;338:a2752. 
61. Hasan M. Readmission of patients to hospital: still ill defined and poorly 
understood. International Journal for Quality in Health Care. 2001;13(3):177-9. 
62. Mueller C, Schur C, O'Connell J. Prescription drug spending: the impact of age 
and chronic disease status. American Journal of Public Health. 1997;87(10):1626-9. 
63. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of 
opioid analgesics in the treatment of cancer pain: evidence-based recommendations 
from the EAPC. The Lancet Oncology. 2012;13(2):e58-e68. 
64. Van den Beuken-van Everdingen M, De Rijke J, Kessels A, Schouten H, Van Kleef 
M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 
40 years. Annals of oncology. 2007;18(9):1437-49. 
 
88 
 
9   Appendices 
Appendix 1: the STROBE checklist 
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the 
abstract 
(b) Provide in the abstract an informative and balanced summary of what was 
done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods 
of selection of participants. Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods 
of case ascertainment and control selection. Give the rationale for the choice 
of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and 
methods of selection of participants 
(b) Cohort study—For matched studies, give matching criteria and number of 
exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the 
number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and 
effect modifiers. Give diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and 
controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking 
account of sampling strategy 
(e) Describe any sensitivity analyses 
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Results 
Participants 13* (a) Report numbers of individuals at each stage of study—e.g. numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, completing 
follow-up, and analysed 
(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (e.g. demographic, clinical, social) and 
information on exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of interest 
(c) Cohort study—Summarise follow-up time (e.g. average and total amount) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 
Case-control study—Report numbers in each exposure category, or summary measures 
of exposure 
Cross-sectional study—Report numbers of outcome events or summary measures 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (e.g. 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and interactions, and 
sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed 
and unexposed groups in cohort and cross-sectional studies. 
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Appendix 2: NHLBI checklist 
Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies 
Criteria Yes No 
Other 
(CD, NR, NA)* 
1. Was the research question or objective in this paper clearly stated?       
2. Was the study population clearly specified and defined?       
3. Was the participation rate of eligible persons at least 50%?       
4. Were all the subjects selected or recruited from the same or similar populations 
(including the same time period)? Were inclusion and exclusion criteria for being in 
the study prespecified and applied uniformly to all participants? 
      
5. Was a sample size justification, power description, or variance and effect 
estimates provided? 
      
6. For the analyses in this paper, were the exposure(s) of interest measured prior to 
the outcome(s) being measured? 
      
7. Was the timeframe sufficient so that one could reasonably expect to see an 
association between exposure and outcome if it existed? 
      
8. For exposures that can vary in amount or level, did the study examine different 
levels of the exposure as related to the outcome (e.g., categories of exposure, or 
exposure measured as continuous variable)? 
      
9. Were the exposure measures (independent variables) clearly defined, valid, 
reliable, and implemented consistently across all study participants? 
      
10. Was the exposure(s) assessed more than once over time?       
11. Were the outcome measures (dependent variables) clearly defined, valid, 
reliable, and implemented consistently across all study participants? 
      
12. Were the outcome assessors blinded to the exposure status of participants?       
13. Was loss to follow-up after baseline 20% or less?       
14. Were key potential confounding variables measured and adjusted statistically 
for their impact on the relationship between exposure(s) and outcome(s)? 
     
Quality Rating (Good, Fair, or Poor) (see guidance) 
Rater #1 initials: 
Rater #2 initials: 
Additional Comments (If POOR, please state why): 
*CD, cannot determine; NA, not applicable; NR, not reported 
Guidance for Assessing the Quality of Observational Cohort and Cross-
Sectional Studies 
The guidance document below is organized by question number from the tool for quality 
assessment of observational cohort and cross-sectional studies. 
Question 1. Research question 
Did the authors describe their goal in conducting this research? Is it easy to understand what 
they were looking to find? This issue is important for any scientific paper of any type. Higher 
quality scientific research explicitly defines a research question. 
Questions 2 and 3. Study population 
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Did the authors describe the group of people from which the study participants were selected 
or recruited, using demographics, location, and time period? If you were to conduct this 
study again, would you know who to recruit, from where, and from what time period? Is the 
cohort population free of the outcomes of interest at the time they were recruited? 
An example would be men over 40 years old with type 2 diabetes who began seeking medical 
care at Phoenix Good Samaritan Hospital between January 1, 1990 and December 31, 1994. 
In this example, the population is clearly described as: (1) who (men over 40 years old with 
type 2 diabetes); (2) where (Phoenix Good Samaritan Hospital); and (3) when (between 
January 1, 1990 and December 31, 1994). Another example is women ages 34 to 59 years of 
age in 1980 who were in the nursing profession and had no known coronary disease, stroke, 
cancer, hypercholesterolemia, or diabetes, and were recruited from the 11 most populous 
States, with contact information obtained from State nursing boards. 
In cohort studies, it is crucial that the population at baseline is free of the outcome of 
interest. For example, the nurses' population above would be an appropriate group in which 
to study incident coronary disease. This information is usually found either in descriptions of 
population recruitment, definitions of variables, or inclusion/exclusion criteria. 
You may need to look at prior papers on methods in order to make the assessment for this 
question. Those papers are usually in the reference list. 
If fewer than 50% of eligible persons participated in the study, then there is concern that the 
study population does not adequately represent the target population. This increases the risk 
of bias. 
Question 4. Groups recruited from the same population and uniform 
eligibility criteria 
Were the inclusion and exclusion criteria developed prior to recruitment or selection of the 
study population? Were the same underlying criteria used for all of the subjects involved? 
This issue is related to the description of the study population, above, and you may find the 
information for both of these questions in the same section of the paper. 
Most cohort studies begin with the selection of the cohort; participants in this cohort are then 
measured or evaluated to determine their exposure status. However, some cohort studies 
may recruit or select exposed participants in a different time or place than unexposed 
participants, especially retrospective cohort studies–which is when data are obtained from 
the past (retrospectively), but the analysis examines exposures prior to outcomes. For 
example, one research question could be whether diabetic men with clinical depression are at 
higher risk for cardiovascular disease than those without clinical depression. So, diabetic men 
with depression might be selected from a mental health clinic, while diabetic men without 
depression might be selected from an internal medicine or endocrinology clinic. This study 
recruits groups from different clinic populations, so this example would get a "no." 
However, the women nurses described in the question above were selected based on the 
same inclusion/exclusion criteria, so that example would get a "yes." 
Question 5. Sample size justification 
Did the authors present their reasons for selecting or recruiting the number of people 
included or analyzed? Do they note or discuss the statistical power of the study? This 
question is about whether or not the study had enough participants to detect an association if 
one truly existed. 
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A paragraph in the methods section of the article may explain the sample size needed to 
detect a hypothesized difference in outcomes. You may also find a discussion of power in the 
discussion section (such as the study had 85 percent power to detect a 20 percent increase 
in the rate of an outcome of interest, with a 2-sided alpha of 0.05). Sometimes estimates of 
variance and/or estimates of effect size are given, instead of sample size calculations. In any 
of these cases, the answer would be "yes." 
However, observational cohort studies often do not report anything about power or sample 
sizes because the analyses are exploratory in nature. In this case, the answer would be "no." 
This is not a "fatal flaw." It just may indicate that attention was not paid to whether the 
study was sufficiently sized to answer a prespecified question–i.e., it may have been an 
exploratory, hypothesis-generating study. 
Question 6. Exposure assessed prior to outcome measurement 
This question is important because, in order to determine whether an exposure causes an 
outcome, the exposure must come before the outcome. 
For some prospective cohort studies, the investigator enrolls the cohort and then determines 
the exposure status of various members of the cohort (large epidemiological studies like 
Framingham used this approach). However, for other cohort studies, the cohort is selected 
based on its exposure status, as in the example above of depressed diabetic men (the 
exposure being depression). Other examples include a cohort identified by its exposure to 
fluoridated drinking water and then compared to a cohort living in an area without fluoridated 
water, or a cohort of military personnel exposed to combat in the Gulf War compared to a 
cohort of military personnel not deployed in a combat zone. 
With either of these types of cohort studies, the cohort is followed forward in time (i.e., 
prospectively) to assess the outcomes that occurred in the exposed members compared to 
nonexposed members of the cohort. Therefore, you begin the study in the present by looking 
at groups that were exposed (or not) to some biological or behavioral factor, intervention, 
etc., and then you follow them forward in time to examine outcomes. If a cohort study is 
conducted properly, the answer to this question should be "yes," since the exposure status of 
members of the cohort was determined at the beginning of the study before the outcomes 
occurred. 
For retrospective cohort studies, the same principal applies. The difference is that, rather 
than identifying a cohort in the present and following them forward in time, the investigators 
go back in time (i.e., retrospectively) and select a cohort based on their exposure status in 
the past and then follow them forward to assess the outcomes that occurred in the exposed 
and nonexposed cohort members. Because in retrospective cohort studies the exposure and 
outcomes may have already occurred (it depends on how long they follow the cohort), it is 
important to make sure that the exposure preceded the outcome. 
Sometimes cross-sectional studies are conducted (or cross-sectional analyses of cohort-study 
data), where the exposures and outcomes are measured during the same timeframe. As a 
result, cross-sectional analyses provide weaker evidence than regular cohort studies 
regarding a potential cauasl relationship between exposures and outcomes. For cross-
sectional analyses, the answer to Question 6 should be "no." 
Question 7. Sufficient timeframe to see an effect 
Did the study allow enough time for a sufficient number of outcomes to occur or be observed, 
or enough time for an exposure to have a biological effect on an outcome? In the examples 
given above, if clinical depression has a biological effect on increasing risk for CVD, such an 
effect may take years. In the other example, if higher dietary sodium increases BP, a short 
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timeframe may be sufficient to assess its association with BP, but a longer timeframe would 
be needed to examine its association with heart attacks. 
The issue of timeframe is important to enable meaningful analysis of the relationships 
between exposures and outcomes to be conducted. This often requires at least several years, 
especially when looking at health outcomes, but it depends on the research question and 
outcomes being examined. 
Cross-sectional analyses allow no time to see an effect, since the exposures and outcomes 
are assessed at the same time, so those would get a "no" response. 
Question 8. Different levels of the exposure of interest 
If the exposure can be defined as a range (examples: drug dosage, amount of physical 
activity, amount of sodium consumed), were multiple categories of that exposure assessed? 
(for example, for drugs: not on the medication, on a low dose, medium dose, high dose; for 
dietary sodium, higher than average U.S. consumption, lower than recommended 
consumption, between the two). Sometimes discrete categories of exposure are not used, 
but instead exposures are measured as continuous variables (for example, mg/day of dietary 
sodium or BP values). 
In any case, studying different levels of exposure (where possible) enables investigators to 
assess trends or dose-response relationships between exposures and outcomes–e.g., the 
higher the exposure, the greater the rate of the health outcome. The presence of trends or 
dose-response relationships lends credibility to the hypothesis of causality between exposure 
and outcome. 
For some exposures, however, this question may not be applicable (e.g., the exposure may 
be a dichotomous variable like living in a rural setting versus an urban setting, or 
vaccinated/not vaccinated with a one-time vaccine). If there are only two possible exposures 
(yes/no), then this question should be given an "NA," and it should not count negatively 
towards the quality rating. 
Question 9. Exposure measures and assessment 
Were the exposure measures defined in detail? Were the tools or methods used to measure 
exposure accurate and reliable–for example, have they been validated or are they objective? 
This issue is important as it influences confidence in the reported exposures. When exposures 
are measured with less accuracy or validity, it is harder to see an association between 
exposure and outcome even if one exists. Also as important is whether the exposures were 
assessed in the same manner within groups and between groups; if not, bias may result. 
For example, retrospective self-report of dietary salt intake is not as valid and reliable as 
prospectively using a standardized dietary log plus testing participants' urine for sodium 
content. Another example is measurement of BP, where there may be quite a difference 
between usual care, where clinicians measure BP however it is done in their practice setting 
(which can vary considerably), and use of trained BP assessors using standardized equipment 
(e.g., the same BP device which has been tested and calibrated) and a standardized protocol 
(e.g., patient is seated for 5 minutes with feet flat on the floor, BP is taken twice in each 
arm, and all four measurements are averaged). In each of these cases, the former would get 
a "no" and the latter a "yes." 
Here is a final example that illustrates the point about why it is important to assess 
exposures consistently across all groups: If people with higher BP (exposed cohort) are seen 
by their providers more frequently than those without elevated BP (nonexposed group), it 
also increases the chances of detecting and documenting changes in health outcomes, 
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including CVD-related events. Therefore, it may lead to the conclusion that higher BP leads to 
more CVD events. This may be true, but it could also be due to the fact that the subjects 
with higher BP were seen more often; thus, more CVD-related events were detected and 
documented simply because they had more encounters with the health care system. Thus, it 
could bias the results and lead to an erroneous conclusion. 
Question 10. Repeated exposure assessment 
Was the exposure for each person measured more than once during the course of the study 
period? Multiple measurements with the same result increase our confidence that the 
exposure status was correctly classified. Also, multiple measurements enable investigators to 
look at changes in exposure over time, for example, people who ate high dietary sodium 
throughout the followup period, compared to those who started out high then reduced their 
intake, compared to those who ate low sodium throughout. Once again, this may not be 
applicable in all cases. In many older studies, exposure was measured only at baseline. 
However, multiple exposure measurements do result in a stronger study design. 
Question 11. Outcome measures 
Were the outcomes defined in detail? Were the tools or methods for measuring outcomes 
accurate and reliable–for example, have they been validated or are they objective? This issue 
is important because it influences confidence in the validity of study results. Also important is 
whether the outcomes were assessed in the same manner within groups and between 
groups. 
An example of an outcome measure that is objective, accurate, and reliable is death–the 
outcome measured with more accuracy than any other. But even with a measure as objective 
as death, there can be differences in the accuracy and reliability of how death was assessed 
by the investigators. Did they base it on an autopsy report, death certificate, death registry, 
or report from a family member? Another example is a study of whether dietary fat intake is 
related to blood cholesterol level (cholesterol level being the outcome), and the cholesterol 
level is measured from fasting blood samples that are all sent to the same laboratory. These 
examples would get a "yes." An example of a "no" would be self-report by subjects that they 
had a heart attack, or self-report of how much they weigh (if body weight is the outcome of 
interest). 
Similar to the example in Question 9, results may be biased if one group (e.g., people with 
high BP) is seen more frequently than another group (people with normal BP) because more 
frequent encounters with the health care system increases the chances of outcomes being 
detected and documented. 
Question 12. Blinding of outcome assessors 
Blinding means that outcome assessors did not know whether the participant was exposed or 
unexposed. It is also sometimes called "masking." The objective is to look for evidence in the 
article that the person(s) assessing the outcome(s) for the study (for example, examining 
medical records to determine the outcomes that occurred in the exposed and comparison 
groups) is masked to the exposure status of the participant. Sometimes the person 
measuring the exposure is the same person conducting the outcome assessment. In this 
case, the outcome assessor would most likely not be blinded to exposure status because they 
also took measurements of exposures. If so, make a note of that in the comments section. 
As you assess this criterion, think about whether it is likely that the person(s) doing the 
outcome assessment would know (or be able to figure out) the exposure status of the study 
participants. If the answer is no, then blinding is adequate. An example of adequate blinding 
of the outcome assessors is to create a separate committee, whose members were not 
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involved in the care of the patient and had no information about the study participants' 
exposure status. The committee would then be provided with copies of participants' medical 
records, which had been stripped of any potential exposure information or personally 
identifiable information. The committee would then review the records for prespecified 
outcomes according to the study protocol. If blinding was not possible, which is sometimes 
the case, mark "NA" and explain the potential for bias. 
Question 13. Followup rate 
Higher overall followup rates are always better than lower followup rates, even though higher 
rates are expected in shorter studies, whereas lower overall followup rates are often seen in 
studies of longer duration. Usually, an acceptable overall followup rate is considered 80 
percent or more of participants whose exposures were measured at baseline. However, this is 
just a general guideline. For example, a 6-month cohort study examining the relationship 
between dietary sodium intake and BP level may have over 90 percent followup, but a 20-
year cohort study examining effects of sodium intake on stroke may have only a 65 percent 
followup rate. 
Question 14. Statistical analyses 
Were key potential confounding variables measured and adjusted for, such as by statistical 
adjustment for baseline differences? Logistic regression or other regression methods are 
often used to account for the influence of variables not of interest. 
This is a key issue in cohort studies, because statistical analyses need to control for potential 
confounders, in contrast to an RCT, where the randomization process controls for potential 
confounders. All key factors that may be associated both with the exposure of interest and 
the outcome–that are not of interest to the research question–should be controlled for in the 
analyses. 
For example, in a study of the relationship between cardiorespiratory fitness and CVD events 
(heart attacks and strokes), the study should control for age, BP, blood cholesterol, and body 
weight, because all of these factors are associated both with low fitness and with CVD 
events. Well-done cohort studies control for multiple potential confounders. 
Some general guidance for determining the overall quality rating of observational cohort and 
cross-sectional studies 
The questions on the form are designed to help you focus on the key concepts for evaluating 
the internal validity of a study. They are not intended to create a list that you simply tally up 
to arrive at a summary judgment of quality. 
Internal validity for cohort studies is the extent to which the results reported in the study can 
truly be attributed to the exposure being evaluated and not to flaws in the design or conduct 
of the study–in other words, the ability of the study to draw associative conclusions about the 
effects of the exposures being studied on outcomes. Any such flaws can increase the risk of 
bias. 
Critical appraisal involves considering the risk of potential for selection bias, information bias, 
measurement bias, or confounding (the mixture of exposures that one cannot tease out from 
each other). Examples of confounding include co-interventions, differences at baseline in 
patient characteristics, and other issues throughout the questions above. High risk of bias 
translates to a rating of poor quality. Low risk of bias translates to a rating of good quality. 
(Thus, the greater the risk of bias, the lower the quality rating of the study.) 
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In addition, the more attention in the study design to issues that can help determine whether 
there is a causal relationship between the exposure and outcome, the higher quality the 
study. These include exposures occurring prior to outcomes, evaluation of a dose-response 
gradient, accuracy of measurement of both exposure and outcome, sufficient timeframe to 
see an effect, and appropriate control for confounding–all concepts reflected in the tool. 
Generally, when you evaluate a study, you will not see a "fatal flaw," but you will find some 
risk of bias. By focusing on the concepts underlying the questions in the quality assessment 
tool, you should ask yourself about the potential for bias in the study you are critically 
appraising. For any box where you check "no" you should ask, "What is the potential risk of 
bias resulting from this flaw in study design or execution?" That is, does this factor cause you 
to doubt the results that are reported in the study or doubt the ability of the study to 
accurately assess an association between exposure and outcome? 
The best approach is to think about the questions in the tool and how each one tells you 
something about the potential for bias in a study. The more you familiarize yourself with the 
key concepts, the more comfortable you will be with critical appraisal. Examples of studies 
rated good, fair, and poor are useful, but each study must be assessed on its own based on 
the details that are reported and consideration of the concepts for minimizing bias. 
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Appendix 3: CASP checklist for review studies
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Appendix 4: CASP checklist for cohort studies 
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Appendix 5: the JBI checklist
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